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Muscle disorders are chronic, progressive conditions, the majority of which are 
without disease modifying treatments. Quality of life (QoL) is reduced in these 
conditions, and alternative methods, such as psychological intervention, may offer ways 
to improve QoL. Previous work has suggested that aberr nt illness perceptions may be 
influential targets for psychological interventions; however, emerging evidence suggests 
that psychological flexibility might offer another treatment target.  
This thesis first presents a longitudinal investigation of the role of these two 
variables, alongside disability level, in explaining life satisfaction and mood measured 
four months later. Participants were recruited from charities and online communities, 
with data collected via online questionnaires. Here, illness perceptions and 
psychological flexibility, but not disability level, were cross-sectionally associated with 
all dependent variables. In prospective analyses psychological flexibility accounted for 
greater variance in life satisfaction and anxiety; while illness perceptions explained 
more variance in depression. However, after controlling for variance in time one 
dependent variables, psychological flexibility alone was predictive of life satisfaction 
and anxiety at time two. Therefore, psychological flexibility represents a possible 
influential target for psychological intervention in muscle disorders. 
Acceptance and Commitment Therapy (ACT) is a psychological intervention 
specifically designed to improve psychological flexibility. Subsequently, the results of 
the empirical study imply that ACT is worthy of trial with muscle disorders. However, 
there has been no comprehensive review of the use of ACT in chronic disease or long-
term conditions. Therefore, Chapter 2 presents a systematic review of ACT as applied to 
chronic disease/long-term conditions. The aims were to collate all ACT interventions 
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with chronic disease/long-term conditions; evaluate their quality and comment on 
efficacy.  
Ovid MEDLINE, EMBASE and Psych Info were searched, with a further search 
of citing articles undertaken using Google Scholar. Studies with mental health or 
chronic pain populations were excluded. Study quality was then rated, with a proportion 
re-rated by a second researcher. Seventeen studies wer  included, of which: eight were 
randomised controlled trials (RCTs), three used pre-post designs, and seven were case 
studies. A broad range of applications were observed (e.g. improving quality of life and 
symptom control, reducing distress) across many diseases/conditions (e.g. HIV, cancer, 
epilepsy). However, study quality was generally low, and many interventions were of 
low intensity. The small number of RCTs per application and lower study quality 
emphasise that ACT is not yet a well-established intervention for chronic disease/long-
term conditions. However, there was promising evidence for certain applications: the 
parenting of children with long-term conditions, seizure-control in epilepsy, 
psychological flexibility and possibly self-managemnt/lifestyle.  
The studies comprising this thesis suggest that, whilst psychological flexibility 
appears influential in muscle disorders, high-quality research into ACT interventions for 
chronic disease/long-term conditions is generally lcking. Therefore one cannot 
confidently generalise from existing studies that ACT will improve outcomes in muscle 
disorders. Thus an evaluation of ACT in the context of muscle disorders is now 
required. This should adhere to the methodological suggestions provided in the 
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Background: Acceptance and Commitment Therapy (ACT), which targets 
psychological flexibility, and illness perceptions i terventions, appear to improve 
quality of life in chronic disease.  
Purpose: To optimize interventions for muscle disorders, after controlling for disability 
level, the relative influence of illness perceptions and psychological flexibility on life 
satisfaction and distress was investigated.  
Methods: Data were collected via online questionnaires. Regression analyses examined 
relationships between disability level, psychological flexibility (experiential avoidance, 
cognitive fusion and valued living) and illness perceptions, and outcomes (cross-
sectionally and 4 months later).  
Results: Illness perceptions and psychological flexibility, but not disability level, were 
cross-sectionally associated with all outcomes. In prospective analyses psychological 
flexibility was most strongly associated with life satisfaction and anxiety; while illness 
perceptions were most strongly associated with depression. After controlling for 
variance in time 1 dependent variables, psychological flexibility alone was predictive of 
life satisfaction and anxiety at time 2. 










Muscle disorders (MDs) are a diverse group of genetic and acquired 
neuromuscular conditions, the majority of which are p ogressive (1). They principally 
affect muscle tissue, which translates into an insid ous decline in physical functioning 
and mobility. Weakness in other muscle groups may cause dysarthria, dysphagia, 
contractures, ptosis and opthalmopariesis. Cardiac and respiratory symptoms may also 
be present, and problematic pain and fatigue are frequently reported (1-4). People with 
MDs experience reduced quality of life when compared to population norms, and mood 
may also be affected (5-7). 
Few disease modifying treatments are available for the majority of MDs and 
there are no cures. Thus, most interventions seek to manage symptomatic 
complications. For example, physiotherapy and orthoses are often provided to enable as 
broad a range of movement as possible, while medication may be prescribed for pain 
and fatigue (1).  
Emerging evidence suggests that cognitive behavioural therapies may offer an 
additional way to improve quality of life and mood in MDs (8); with promising results 
observed  in a recent trial of cognitive behavioural therapy reducing fatigue (9). This, 
the only published trial of a psychological intervention for MDs, utilised a three-arm 
randomized-controlled trial (RCT) design - comparing cognitive behavioural therapy to 
aerobic exercise training and treatment as usual. Here aspects of cognitive therapy 
targeted ‘dysfunctional cognitions’ regarding fatigue, sleep, activity and 
catastrophizing, amongst a broad range of other therapeutic methods – with sessions 
also aimed at improving communication between people with MDs and care-
givers/relatives. Results showed significant improvements in fatigue in both the aerobic 
exercise training and the cognitive behavioural therapy group; however, only the 
cognitive behavioural therapy group showed significant improvements in social 
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participation and sleep compared to controls. Alongside these additional benefits the 
cognitive behavioural therapy treatment was much shorter in duration than the aerobic 
exercise training, suggesting greater cost-effectivness. However, this trial suffered 
from much poorer adherence to treatment in the aerobic exercise training group, which 
may account for the differential outcomes. Indeed, the control group was treatment as 
usual (i.e. without a control for supportive therapy, empathic concern etc), and so it 
could also be argued that a placebo effect/impact of non-specific therapy factors were 
not adequately controlled.  
This sole existing trial of a psychological intervention in MD sought to improve 
fatigue, but not QoL or mood. Given that these important outcomes also appear to be 
affected by living with MDs (5, 7), an outstanding central question for psychological 
intervention development is which cognitive and behavioral variables should be 
optimally targeted to improve quality of life or mood? The present study examines the 
relative importance of two possible targets for intervention: illness perceptions and 
psychological flexibility.  
Illness Perceptions 
Illness perceptions are cognitions formed in respone to a health threat (10). 
They include beliefs about the time-course of the healt  threat, its consequences and if it 
can be cured or controlled amongst a range of other beliefs. Illness perceptions are 
theorized to influence the methods that a person will use to manage or cope with their 
illness; the success or failure of these methods will then affect quality of life and mood 
(11). In agreement with this assumption, aberrant illness perceptions are often 
associated with negative outcomes in chronic disease (12, 13). Subsequently, 
interventions which target illness perceptions have be n developed. These provide 
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education about the disease in question and challenge inaccurate beliefs as a means to 
improve disease self-management (10).   
Three studies have observed significant associations between illness perceptions 
and quality of life and mood in MDs (14-16), even after controlling for disability level. 
This provides promising evidence that illness perceptions are suitable targets for 
intervention in MDs. However, all these studies employed cross-sectional designs. This 
is problematic because it is conceivable that low quality of life and mood might cause 
aberrant illness perceptions as well as vice versa. An lyses using prospective designs 
would allow greater understanding of the direction of this relationship.   
Psychological Flexibility 
In contrast, Acceptance and Commitment Therapy (ACT) (17) proposes that 
one’s relationship with their thoughts may have a greater influence over behavior than 
the content of these thoughts (for example, illness perceptions). ACT posits that a 
process called psychological flexibility has a key influence on quality of life and mood, 
especially in the face of adversity such as that presented by chronic illness. 
Psychological flexibility is defined as: being open, aware and in contact with present 
moment, flexibly pursuing behaviours which are in line with one’s chosen values (18). 
It can be broken down into six overlapping and interdependent sub-processes: being 
aware of what is personally important (values) on an ongoing basis (present-moment-
focus); taking steps towards these values (committed action) whilst accepting 
subsequent uncomfortable private experiences such as pain, embarrassment or negative 
thoughts (experiential acceptance); within this, being able to see thoughts as transient 
mental events (cognitive defusion) which are separate f om the person who is doing the 
thinking (self-as-context).    
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Psychological flexibility has shown strong relationships with a range of 
outcomes in other conditions, such as pain interfernce, mood and functioning in 
chronic pain patients (19) and adjustment in other neuromuscular conditions (20). There 
is emerging evidence that psychological flexibility may also be influential in MDs. For 
example, one study observed that willingness to experience musculoskeletal pain 
(experiential acceptance) when this facilitated valued-activity, was negatively 
associated with depression, while engagement in valued activity (valued-living) was 
negatively associated with depression and positively associated with quality of life (21). 
Another study observed that fear of experiencing discrimination (cognitive fusion) had a 
greater negative correlation with quality of life than did actual experienced 
discrimination (22). To our knowledge the prospective influence of psychological 
flexibility on quality of life or mood has not yet been investigated in MDs. 
Psychological flexibility is postulated to influence one’s ability to align their behaviours 
with deeply held values and stay in contact with the present moment as opposed to 
being drawn into unhelpful focus on worries or fears. This despite unpleasant and 
challenging experiences -  such as ongoing pain, fatigue, illness related worries- which 
may occur as one lives with a MD. Thus, since psychological flexibility is theorized to 
impact on one’s ability to undertake personally meaningful activities (both personal and 
illness-related), as opposed to solely one’s ability to manage their illness it is a more 
general, and possibly more influential , process than disease self-management. Thus 
psychological flexibility may prove more influential on outcomes than illness 
perceptions.  
The Present Study 
This study aimed to assess the cross-sectional and prospective influence of 
validated measures of illness perceptions, and facets of psychological flexibility 
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(experiential avoidance, cognitive fusion and valued living) on life satisfaction and 
mood. As described in the preceding paragraph above thes  facets of psychological 
flexibility were chosen based on existing studies (21, 22), since they appear to be key 
processes in successful living with MDs, (8, 21).  
As all available brief quality of life measures were confounded by items 
capturing physical functioning, a measure of life satisfaction was instead used in the 
present study (Satisfaction With Life Scale (23)). Life satisfaction is conceptually 
commensurate to quality of life, defined as:  “…a global evaluation by the person of his 
or her life.” (24), p150. These outcomes life satisf ction (i.e. QoL) and mood were 
deemed important since both (5, 7) are reduced in MD, and are appropriate treatment 
targets for forthcoming psychological intervention (see Graham et al., (2015)(8)) 
We hypothesized that both illness perceptions and fcets of psychological 
flexibility would be strongly correlated with life satisfaction, anxiety and depression. 
We expected psychological flexibility to have a stronger prospective influence on life 
satisfaction and mood measured four months later.  
 
METHODS 
Participants and Procedure 
Participants were recruited via a news story published on the Muscular 
Dystrophy Campaign (United Kingdom) website. This contained a link to a website 
which comprised information regarding the study, a consent form and the first 
questionnaire battery. Before giving consent potential participants assessed themselves 
against the inclusion/exclusion criteria. Prospective participants were eligible if they 
had a diagnosis of MD with duration of greater than six months and were aged 18 - 75 
years. They were ineligible if: they had major active co-morbidities unrelated to MD 
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(such as stroke); experienced cognitive impairment or had myotonic dystrophy 
(Myotonic Dystrophy is associated with cognitive impairment (25)); were unable to 
read English; had major diagnosed active mental health co-morbidities, for example 
psychosis or major depression; or, were currently participating in treatment intervention 
studies. 
Participants then gave consent, entered their e-mail address and progressed to 
the first questionnaire battery. This battery contained measures of dependent and 
independent variables (listed below) and recorded demographics (MD diagnosis, age, 
gender, and years since they first noticed symptoms). Four months later, participants 
were e-mailed a link to the second questionnaire battery. This again recorded the 
dependent variables but omitted the independent variables (to reduce participant 
burden), with the exception of disability level and illness perceptions (illness 
perceptions data are not presented here). Favorable ethical opinion was given by the 
Health in Social Sciences departmental ethics committee at the University of 
Edinburgh.  
Measures 
Dependent Variables  
As previously described, The Satisfaction With Living Scale (SWLS) (23) was 
used instead of a measure of QoL since it records a person’s estimation of how their 
experience of life meets their expectations, but is not confounded by items related to 
disease severity or symptoms. It is a seven item, uni-dimensional measure of life 
satisfaction. Scores can range from 0-35, with higher scores indicating greater life 
satisfaction. It showed good internal consistency i a previous study with people with 
MDs (26), and strong psychometric properties (discriminant validity, factor structure, 
and concurrent validity) in a range of groups, including chronic illness groups (24, 27). 
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In the present study the SWLS showed a very good level of internal consistency (α = 
.88).  
The Generalised Anxiety Disorder 7-item Scale (GAD-7) (28) was chosen as 
a measure of anxiety not only because it is well validated  (29), but also brief – just 
seven-items- meaning that it represents a low participant burden. Scores can range from 
0-21, with higher scores indicating more severe anxiety. Psychometric evaluation in a 
large sample of people with another neuromuscular disease (multiple sclerosis) revealed 
reliability and internal validity (30). The internal consistency of this measure was 
excellent (α = .90). 
The 9-item version of the Patient Health Questionnaire (PHQ-9) (31) is a 
(nine item) measure of depression. As with the GAD-7 it is well validated and brief 
(31), and has shown good psychometric properties in a range of other chronic illnesses 
e.g. (32, 33). Though to our knowledge it has not yet been applied in studies with MD 
populations. Scores can range from 0-27, with higher scores indicating more severe 
depression.  The internal consistency of this measur  was also very good (α = .86). 
 
Independent Variables  
The Stanford Health Assessment Questionnaire – Disability Index (HAQ-
DI) (34) was chosen as it is a well-validated  measure of impairment in physical 
functioning, or disability level (35), which is not confounded by items measuring mood 
or psychological constructs. It contains eight activity domains (dressing, arising, eating, 
walking, hygiene, reach, grip, and activities), butdoes not record impairment in social 
or emotional functioning. There are various ways to c re the HAQ-DI; we used the 
alternative scoring method which does not take into consideration the use of aides and 
devices and averages the domains to give one total score (range 0 – 3)(36). Higher 
scores indicate greater functional impairment. Previous studies with chronic disease 
populations (35) (including with MD (14, 16)) have observed good reliability, and 
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validity. In the present study, internal consistency of the sub-scales ranged from α = .71 
to α = .89. 
The Brief Illness Perception Questionnaire (Brief IPQ) (37) was used to 
capture illness perceptions. It was chosen as it is a brief measure of illness beliefs, not 
confounded by aspects of psychological flexibility.  In the present study eight of nine 
possible domains were utilized. Scores on each domain can range from 0 -10. Higher 
scores indicate a stronger belief that: MD has many symptoms (identity), it will be 
chronic as opposed to acute (timeline acute/chronic), it has many consequences 
(consequences), it can be controlled by ones behavior (personal control) or by treatment 
(treatment control), it is understandable (illness coherence) or it causes distress 
(emotional representation) and concern (concern). These domains can be summed to 
give a total score, which quantifies the extent to which the illness is viewed as 
threatening (37). In an initial validation study the Brief IPQ showed good test- retest 
reliability and concurrent validity (37); however, a more recent qualitative study using 
cognitive interviewing, has called into question the content validity of the measure (38). 
In the present study the internal consistency for the combined score of the Brief IPQ 
was very poor (Cronbach’s α = .52). Thus exploratory factor analyses were undertak n 
using principal components analysis (varimax rotatin) (see Appendix i). The number 
of factors extracted was based on Kaiser’s criterion (39) and inspection of the scree plot 
(40). This yielded three latent variables; however, only one showed acceptable internal 
and conceptual consistency (Cronbach’s α = .71). This variable comprised the 
consequences, identity, emotional representation and co cern domains; thus, it appears 
to capture the level of threat represented by MD - henceforth called IPQ Threat. 
The Cognitive Fusion Questionnaire (CFQ) (41) is a single-domain measure 
of cognitive fusion: “the tendency for behaviour to be overly regulated and influenced 
by cognition, compared to other sources of behaviorl nfluence”(41). It has seven 
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items, and scores can range from 7-49, with a higher score indicating greater cognitive 
fusion. Here, internal consistency was excellent (α = .95). The CFQ is a new measure; 
however, initial validation in neuromuscular diseas (multiple sclerosis) showed 
acceptable psychometric properties and confirmed th unidimensional factor structure 
(41). 
The Acceptance and Action Questionnaire (AAQ)(42) is a uni-dimensional 
questionnaire which measures experiential avoidance, defined as: a regulatory strategy 
comprising attempts to control or avoid unpleasant thoughts, feelings and/or bodily 
sensations (43). The AAQ consists of nine items. Scores can range from 7-63, with 
higher scores indicating greater experiential avoidance. A large validation study with 
people with a range of chronic diseases has shown acceptable validity (44). In the 
present study the internal consistency was acceptabl  (α = .73). A newer version of the 
AAQ (45) was not used as it is designed to capture all facets of psychological flexibility 
within one scale, while the present version is focused on recoding experiential 
avoidance alone. 
The Engaged Living Scale (ELS) (46) is a 16 item measure of valued living, 
specifically derived from the engaged response style of valued-living implicit in ACT. It 
has a range of 0-80, with higher scores indicating greater valued-living. It is a newer 
measure of valued living, it was chosen because of go d face validity for the construct 
of valued-living. In a recent validation study it has shown excellent internal consistency 
and concurrent validity (46). Indeed, in the present study excellent internal consistency 
was apparent (Cronbach’s α = .94). 
Data analyses plan and statistics 
Three regression analyses were undertaken for each dependent variable. The 
first regression analysis assessed the cross-sectional relationship between dependent and 
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independent variables both measured at time one. The second, the prospective 
association between time 1 variables and dependent variables measured 4 months later 
(time 2). The third, assessed the relationship betwe n independent variables measured at 
time 1 and dependent variables at time 2 while controlling for variance in the dependent 
variable measured at time 1. Controlling for time 1 variance means that remaining 
variance is likely to be unique to the time 2 dependent variable. Thus, it can be inferred 
that variance in the T1 independent variable is antecedent to unique variance arising in 
the dependent variable at T2. Unlike in previous stdies (14, 16), this allows one to 
investigate a direction of relationship, with data not confounded by cross-sectional 
relationships between dependent and independent variables (as would be the case if T1 
variance in the dependent variable is not controlled). Change scores were not used since 
there were only two measurement points in the study (as opposed to three or more), 
meaning that variance in the independent variable would not be antecedent to change. 
However, there are two alternative methods which would allow one to account for T1 
variance (a., absolute change with T1 score included as a covariate; b., residualized T2 
score as the dependent variable) (47). In a detailed review, Dalecki & Willits (1991) 
suggest that all of these ‘result in identical interpr tations of the relationship between 
substantive variables and change’, p126 para 1.    
In all regression analyses independent variables were entered in the following 
steps: disability level (HAQ-DI), followed by illness perceptions (IPQ threat), then 
facets of psychological flexibility (valued-living [ELS]; cognitive fusion [CFQ]; 
experiential avoidance [AAQ]).  In the regressions which controlled for time 1 levels of 
the dependent variable, the time 1 dependent variable was entered as a preliminary first 
step.   
 24
A power calculation, undertaken using the G-Power program (48) assuming a 
medium effect size and a power (I – β err prob) of 0.80, estimated a sample size of N = 
98 were required to complete both questionnaires. 
 
RESULTS 
Description of cohort 
At time 1, 191 participants completed all items. Of this group, 137 (71.72%) 
completed the second questionnaire battery. Only those completing both batteries were 
included in the analyses. Mann-Whitney U Tests (used due to unequal sample sizes and 
non-normality) and chi-square tests, corrected for multiple comparisons, revealed no 
significant differences between those who completed both questionnaires batteries and 
those who completed just battery one. The main included MD diagnoses groups were: 
limb-girdle muscular dystrophy (N=42); facioscapulohumeral muscular dystrophy (N = 
28); inclusion body myositis (N =20); Becker muscular dystrophy (N =13) polymyositis 
and dermatomyositis (N = 7). The remainder (N =27) had a range of other MDs, 
including: oculopharyngeal muscular dystrophy, Emery-D eifuss muscular dystrophy, 
and Bethlem myopathy. Upon entry into the study, the average age of participants was 
46.74 years (SD = 13.56), while the average number of years with symptoms was 23.19 
years (SD = 14.00). The sample comprised more females (N = 80) than males (N=57).  
Preliminary Data Analyses  
Life satisfaction significantly worsened over the period of study, (T1 Mean: 
18.54 [SD = 7.79], T2 Mean: 17.01 [SD = 7.52] t(136) = 3.23; p < .01, d = .21) but no 
significant changes in anxiety (Z = -.36, p = .72, d = .04), or depression (Z = -.17, p = 
.86, d = .05) were observed (Table 1). Disability level significantly increased over this 
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time-period (Z = -2.38, p = .02, d = .31), though this increase was small (Median [SE]
T1 = 2.13 [0.72], Mean [SD] T1 = 2.02[0.78]; Median [SE] T2 = 2.13 [0.60], Mean 
[SD] T2 = 2.08 [0.72]). With the exception of disability level, significant and mostly 
moderate to strong correlations between all variables were evident. By contrast, 




Table 1.1. Means *(standard deviations) and inter-correlations (Pearson’s r) 


























1. SWLS T1 18.54 
(7.79) 
 -.49** -.52** -.11  -52** -.57**  .38**  .74** .72** -.43** -.40** 
2. GAD-7 T1 4.31       
(4.4) 
   .79**   .02   .50**   .53**    .60**   - .56** -.38** .75** .67** 
3. PHQ-9 T1 6.58  
(5.36) 










     .53** .46** -.44** -.44** .40** .43** 
6. AAQ T1 32.88 
(8.90) 
      .58** -.66** -.51** .50** .48** 
7. CFQ T1 19.96 
(9.56) 
       -.53** -.23** .52** .43** 
8. ELS T1 54.50 
(13.37) 
        .56** .55** -.45** 
9. SWLS T2 17.01 
(7.52) 










           
*Significant association at less than or equal to p =.05. 
**Significant association at less than or equal to p=.01. 
aWhere appropriate, transformed variables were used; pr sented means (SD) are for untransformed 
variables. 
 
AAQ = Acceptance and Action Questionnaire (experiential avoidance); CFQ = Cognitive Fusion 
Questionnaire (cognitive fusion); ELS = Engaged Living Scale (valued-living); GAD-7 = Generalized 
Anxiety Disorder 7 item Scale (anxiety); HAQ-DI = Health Assessment Questionnaire – Disability Index 
(disability level); IPQ Threat = Brief Illness Percption Questionnaire Threat Scale (illness perceptions); 
PHQ-9 = Patient Health Questionnaire 9 item Scale (depression); SWLS= Satisfaction with Life Scale 
(life satisfaction)  
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Regression analyses  
The assumptions for regression were met, with some exc ptions; HAQ-DI, CFQ, 
GAD 7 and PHQ-9 variables were significantly skewed (Appendix ii). These variables 
were transformed; however, this resulted in marked improved normality for just the 
CFQ and HAQ-DI variables. Thus, where GAD-7 and PHQ-9 were the dependent 
variables, robust regression procedures -with 5000 bootstrapped samples- were also 
employed. Given that the achieved sample size exceeded that a priori sample size 
calculation based on a medium effect size, the regression analysis should be able to 
detect a small-to-medium effect size. 
In the cross-sectional analyses illness perceptions (∆R2 = 0.26-0.27, p <.001) and 
most facets of psychological flexibility (∆R2 = 0.17-0.43, p <.001) explained significant 
proportions of variance in all dependent variables (Tables 1.2-1.4, left section; 
Appendix iii). However, notably experiential avoidance did not explain significant 
proportions of variance in any cross-sectional regression (β =-.10-.08, p = .23-69). In 
the prospective analyses (Tables 1.2-1.4, middle section; Appendix iii) facets of 
psychological flexibility accounted for more variance in life satisfaction (∆R2 = 0.23, p 
<.001) and anxiety (∆R2 = 0.22, p <.001) measured 4 months later, while illness 
perceptions explained more variance in depression (∆R2 = 0.19, p <.001) measured 4 
months later. In the prospective analyses which controlled for time 1 variance in the 
dependent variable (Tables 1.2-1.4, right section; Appendix iii) most of the variance in 
each time 2 dependent variable was explained by the respective time 1 dependent 
variable (∆R2 = 0.52-0.68, p <.001). Nonetheless psychological flexibility explained 
small but significant proportions of additional variance in life satisfaction (∆R2 = 0.04, p 
= .01) and anxiety (∆R2 = 0.03 p = .04); these proportions of variance are roughly 
analogous to a small-to-medium effect size for change. Experiential avoidance (β = -.22, 
p = .01) was negatively associated with life satisfaction; while cognitive fusion (β =.22, 
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p =.01) was positively associated with this outcome. No one facet of psychological 
flexibility was a significant predictor of anxiety, rather a combination of the included 
variables predicted a significant proportion of variance.  Illness perceptions were not 
predictive of variance in any of these regressions (∆R2 = 0.00-0.01, p = .17-.99) and no 
independent variables were predictive of variance i depression. Disability level did not 
explain a significant proportion of variance in any cross-sectional (∆R2 = - 0.01-0.01, p 





















Table 1.2. Three regressions showing the cross-sectional and prospective influence 
of independent variables on life satisfaction (SWLS) 
 
A.Crossectional: all variables at T1 
B. Prospective: Independent variables 
at T1; Dependent variables at T2 
C. Prospective: Independent variables at T1; 
Dependent variables at T2 controlling for T1. 
 
 
Step 1 Step 2 Step 3  Step 1 Step 2 Step 3 
 
Step 1 Step 2 Step 3 Step 4 
        
SWLS 





DI -.10 .01 -.07 
HAQ-
DI  -.02 .00 -.02 
IPQ-
Threat  -.52** -.22** 
IPQ-
Threat  -.45** -.23** 
IPQ-
Threat   -.10 -.10 
AAQ   -.10 AAQ   -.28** AAQ    -.22** 
CFQ   .13 CFQ    .30** CFQ    .22** 
ELS   .66** ELS    .45** ELS    .06 
∆F 1.68 47.92 39.22 ∆F 1.25 32.34 17.65 ∆F 147.31 0.07 1.95 3.65 
∆R2 .01 .26** .34** ∆R
2 .01 .19** .23** ∆R
2 .52** .00 .01 .04* 
























*Significant association at less than p =.05. 
**
 
Significant association at less than or equal to p=.01. 
 
AAQ = Acceptance and Action Questionnaire (experiential avoidance); CFQ = Cognitive Fusion Questionnaire 
(cognitive fusion); ELS = Engaged Living Scale (valued-living); GAD-7 = Generalized Anxiety Disorder 7 item 
Scale (anxiety); HAQ-DI = Health Assessment Questionnaire – Disability Index (disability level); IPQ Threat = Brief 
Illness Perception Questionnaire Threat Scale (illness perceptions); PHQ-9 = Patient Health Questionnare 9 item 











Table 1.3. Three regressions showing the cross-sectional and prospective influence 
of independent variables on anxiety (GAD-7)b 
  
A. Crossectional: all variables at T1 
B. Prospective: Independent variables 
at T1; Dependent variables at T2 
C. Prospective: Independent variables at T1; 
Dependent variables at T2 controlling for T1. 
 
 
Step 1 Step 2 Step 3  Step 1 Step 2 Step 3 
 
Step 1 Step 2 Step 3 Step 4 
        
GAD7 
T1 .75** .75** .71** .59* 




DI -.07 -.17* -.11 
HAQ-
DI  -.09 -.10 -.08 
IPQ-
Threat  .52** .20* 
IPQ-
Threat  .44** .12 
IPQ-
Threat   .09 .00 
AAQ   .03 AAQ   .06 AAQ    .05 
CFQ   .38** CFQ   .31** CFQ    .08 
ELS   -.23* ELS   -.27** ELS    -.14 
∆F .06 46.18 19.75 ∆F 0.64 30.09 16.53 ∆F 168.07 2.20 1.00 2.78 
∆R2 .00 .26** .23** ∆R
2 .01 .18** .22** ∆R























*Significant association at less than p =.05. 
**
 
Significant association at less than or equal to p=.01. 
b Bootstrapped p-values reported.  
 
AAQ = Acceptance and Action Questionnaire (experiential avoidance); CFQ = Cognitive Fusion Questionnaire 
(cognitive fusion); ELS = Engaged Living Scale (valued-living); GAD-7 = Generalized Anxiety Disorder 7 item 
Scale (anxiety); HAQ-DI = Health Assessment Questionnaire – Disability Index (disability level); IPQ Threat = Brief 
Illness Perception Questionnaire Threat Scale (illness perceptions); PHQ-9 = Patient Health Questionnare 9 item 











Table 1.4. Three regressions showing the cross-sectional and prospective influence 
of independent variables on depression (PHQ-9)c    
 
 
A. Crossectional: all variables at T1 
B. Prospective: Independent variables 
at T1; Dependent variables at T2 
C. Prospective: Independent variables at T1; 
Dependent variables at T2 controlling for T1. 
 
 
Step 1 Step 2 Step 3  Step 1 Step 2 Step 3 
 
Step 1 Step 2 Step 3 Step 4 
        
PHQ9 
T1 .83** .83** .83** .82** 




DI .06 -.04 .01 
HAQ-
DI  -.01 -.01 -.01 
IPQ-
Threat  .54** .26* 
IPQ-
Threat  .44** .19  
IPQ-
Threat   .00 -.02 
AAQ   .08 AAQ   .18  AAQ    .11 
CFQ   .20* CFQ   .16 CFQ    -.01 
ELS   -.28** ELS   -.16 ELS    .07 
∆F 0.95 50.53 13.06 ∆F 0.50 30.79 7.79 ∆F 291.06 .03 .00 .84 
∆R2 .01 .27** .17** ∆R
2 .00 .19** .12** ∆R


















.77 - - 
-.02 -
.04 
*Significant association at less than p =.05. 
**
 
Significant association at less than or equal to p=.01. 
c Bootstrapped p-values reported.  
 
AAQ = Acceptance and Action Questionnaire (experiential avoidance); CFQ = Cognitive Fusion Questionnaire 
(cognitive fusion); ELS = Engaged Living Scale (valued-living); GAD-7 = Generalized Anxiety Disorder 7 item 
Scale (anxiety); HAQ-DI = Health Assessment Questionnaire – Disability Index (disability level); IPQ Threat = Brief 
Illness Perception Questionnaire Threat Scale (illness perceptions); PHQ-9 = Patient Health Questionnare 9 item 











As expected the cross-sectional analyses observed both illness perceptions and 
psychological flexibility to be strongly related to life satisfaction, anxiety and 
depression; while no association between disability level and these dependent variables 
was noted. Prospective analyses showed that psychologica  flexibility at time 1 
accounted for more variance in the life satisfaction and anxiety measured 4 months 
later, while illness perceptions explained more variance in depression measured 4 
months later. The most persuasive analyses were thos  t at controlled for variance in 
the time 1 variables; as the remaining variance arises at time 2 the independent variables 
are thus likely to be antecedent to this. Not unexpectedly, given the short latency 
between measurements, the time one dependent variables accounted for large 
proportions of the variance in the time 2 dependent variables. Nonetheless, baseline 
psychological flexibility, but not illness perceptions, predicted small but significant 
proportions of additional variance in both life sati faction and anxiety measured four 
months later. However, no independent variables predicted significant proportions of 
variance in depression.  
Thus, as the average disability level of participants i creased between the two 
time-points, the present results suggest that psychological flexibility may buffer 
declines in life satisfaction or worsening anxiety as disability level increases. In 
contrast, illness perceptions, whilst cross-sectionally associated, showed no significant 
prospective influence on life-satisfaction and mood. The success of psychological 
flexibility in predicting later outcomes may lie inits ability to capture the cognitive-
behavioural processes which might interfere with or accentuate one’s ability to pursue 
personally meaningful activity. This focus on over-arching values as opposed to disease 
self-management is a key difference between the models from which illness perceptions 
and psychological flexibility are derived.  
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The lack of influence of illness perceptions may also be explained by the limited 
role for disease self-management in MDs, given that few available treatments exist. 
Illness perceptions are perhaps likely to have greate  influence in diseases where 
ineffective self-management might strongly interfere with valued-living outside of 
illness (e.g. diabetes, renal disease, cardiovasculr disease) (49-51).  
Nonetheless these findings lend support to the argument that cognitive 
behavioural interventions for MDs may benefit from using an ACT framework (8). 
Indeed, there is a growing evidence base for ACT interventions with chronic health 
conditions (52-54). 
Interesting relationships between aspects of psychological flexibility and later 
outcomes were also observed in the present study. In agreement with a study of chronic 
pain in MDs (Kratz et al., 2013), later life satisfaction was negatively related to 
experiential avoidance. However, surprisingly life satisfaction was also positively 
related to cognitive fusion. Cumulatively this suggests that life satisfaction benefits 
from a) viewing thoughts as real literal events (cognitive fusion) while also, b) showing 
openness to experiencing unpleasant private events, such as difficult thoughts and 
feelings (experiential acceptance) when doing do serve  ones values. This may align 
with an attitude of ‘stoic’ acceptance – in other words, of ‘just getting on with it’ - 
which showed positive associations with quality of life in an earlier study with MDs 
(55). 
In the present study, psychological flexibility predicted significant proportions 
of variance in later anxiety. This adds to the litera ure which suggests that psychological 
flexibility influences anxiety across populations (56-58). The lack of any predictor 
variables to explain variance in later depression, when initial depression was controlled 
may be explained by lack of change in depression scre  over time. While it remains 
possible that neither psychological flexibility or illness perceptions are predictive of 
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depression, positive associations between psychological flexibility (56-58) and aberrant 
illness perceptions (10) and depression have been noted in other populations. Thus, 
future studies might benefit from measuring depression over a longer period of time to 
allow for greater variation. 
 
Limitations 
While these analyses offer the strongest evidence to date that psychological 
flexibility influences life satisfaction/quality of life or anxiety in MDs, we cannot rule 
out the influence of unmeasured variables which affect both psychological flexibility 
and outcome variables. In addition, due to the entry of baseline dependent variables as 
controls the proportions of explained variance in pros ective analyses were low. Thus 
experimental studies which manipulate independent variables – perhaps in an 
intervention study - would be required to make claims regarding causality and indicate 
whether these small proportions of variance are clinically meaningful.  
The current sample was also drawn from online communities as opposed to 
hospital clinics, and was a self-selecting group and may not be representative of the true 
population.  Several exclusion criteria (e.g. cognitive impairment, psychiatric 
diagnoses) were used to minimize the risk of someone without capacity consenting to 
take part; though meeting either criteria is far from  sufficient to infer that one to lacks 
capacity, we assumed that lack of capacity may be more likely in these groups. This 
conservative approach may have limited the representativeness of the sample, compared 
to those seen in clinic: arguably a subsequent intervention would be more likely to be 
applied to those with high levels of mood disturbance. Indeed, further, one could also 
argue that it might have reduced the amount of variation in certain outcome measures – 
especially mood. This may have reduced the amounts of free variance which could be 
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open to explanation by the independent variables. Also, independent variables 
themselves may have also been affected by this loss in variance – one might expect 
psychological flexibility to differ in groups with psychiatric diagnoses.  Conversely, one 
further draw-back of online recruitment was that participants assessed themselves 
against the inclusion/exclusion criteria, and it isthus we cannot exclude the possibility 
that those who did not meet these criteria- indeed even those without MDs at all - may 
have taken part. Nonetheless,  interestingly, the demographic composition of the present 
sample was strikingly similar (age, years with muscle disease, and range and proportion 
of different MDs) to an earlier sample which was drawn from UK National Health 
Service clinics (14).   
Also, although we compared those who completed questionnaires at both time-
points to those who completed them at just one time-point on all included measures and 
observed no significant difference between these groups, it remains possible that these 
groups did differ on an unmeasured variable (e.g. attachment, pain, motivation), or that 
by T2 their condition, mood or life satisfaction may have deteriorated greatly such that 
they withdrew from the study. Thus, our assumption hat responses are missing at 
random may be inaccurate. This possibility again calls into question the generalizability 
of our findings. This point is particularly important given that only small (to medium) 
effect sizes were observed throughout. Indeed, the 95% CI around each change in R2 
was quite broad, suggesting imprecision in the resultant R2 change scores. Thus 
replication would be required to achieve greater certainty about these results. 
Another limitation was that, due to problems with internal consistency, half of 
the domains from the Brief IPQ were not used. This may have occurred because several 
of the items (e.g. treatment control or personal control) may not be applicable to MDs, 
which are generally without treatment.  Another explanation for this is that the negative 
schema proposed by Broadbent et al., (2006)(37), are not necessarily negative in MDs, 
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for example greater illness coherence and less permanent timeline beliefs are not 
necessarily indicative of positive schemata in MDs  (59). It could thus be argued that 
potentially influential data were not included. However, the four domains which were 
included were those most strongly and consistently related to domains of QoL and 
mood in an earlier study (14), with the resultant reduced-item scale conceptually 
commensurate to the full-item scale (measuring illness threat).  
CONCLUSION  
Psychological flexibility was a stronger prospective predictor of life satisfaction 
and anxiety than illness perceptions. This aligns with the view that ACT may be 
efficacious for improving life satisfaction and anxiety in MDs.  
 
NEXT STEPS IN THE THESIS 
The results of this chapter suggest that ACT might improve outcomes in muscle 
disorders. A next step would be to investigate the evidence base for the use of ACT in 
chronic diseases and long-term conditions. This would allow us to establish how ACT 
has been applied in such contexts, and whether it appears to have efficacy for improving 
salient outcomes. 
One could argue that if ACT has convincing efficacy (and safety) for QoL/life 
satisfaction and distress in other long-term conditions, then, since the contexts are 
directly comparable, it can be applied clinically in muscle disorder care. However, if 
there is a lack of evidence then feasibility studies and randomised controlled trials are 
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ABSTRACT 
Many have suggested that Acceptance and Commitment Therapy (ACT) may be 
particularly effective for improving outcomes in chronic disease/long-term conditions, 
and ACT techniques are now being used clinically. However, review of ACT in this 
context is lacking, and the state of evidence has not been clearly described. This 
systematic review aimed to: collate all ACT interventions with chronic disease/long-
term conditions; evaluate their quality; and, comment on efficacy. Ovid MEDLINE, 
EMBASE and Psych Info were searched. Studies with mental health or chronic pain 
populations were excluded. Study quality was then rated, with a proportion re-rated by a 
second researcher. Seventeen studies were included: eight were randomised controlled 
trials (RCTs), three used pre-post designs, and six were case studies. A broad range of 
applications were observed (e.g. improving quality of life and symptom control, 
reducing distress) across many diseases/conditions (e.g. HIV, cancer, epilepsy). 
However, study quality was generally low, and many interventions were of low 
intensity. The small number of RCTs per application and lower study quality emphasise 
that ACT is not yet a well-established intervention f r chronic disease/long-term 
conditions. However, there was promising evidence for certain applications: parenting 
of children with long-term conditions, seizure-contr l in epilepsy, psychological 
flexibility and possibly self-management. 
 
 
Key words: Acceptance and Commitment Therapy; systema ic review; chronic disease; 




Successful living with a chronic disease/long-term condition such as diabetes, 
HIV, cancer or brain injury (henceforth called long-term conditions) is likely to involve 
a range of adaptive self-management behaviours, for example: adhering to medications, 
or amending one’s activities and diet. A parallel process of psychological adjustment 
may also occur, involving evaluation of the functional impact of the condition and the 
regulation of any resultant distress (Leventhal, Nerenz, & Steele, 1984). The recognition 
that a person’s own self-management behaviours and emotional responses may impact 
on their quality of life and other meaningful outcomes, has led to the application of 
cognitive behavioural interventions which target beliefs, behaviours and emotional 
regulation to improve outcomes (Barlow, Wright, Sheasby, Turner, & Hainsworth, 
2002; Graham, Simmons, Stuart, & Rose, 2014; Petrie & Weinman, 2012).  
Cognitive and behavioural interventions for long-term conditions 
Interventions derived from traditional cognitive therapy have been widely 
applied to improve distress and self-management in long-term conditions (Greer et al., 
1992; Hind et al., 2014; Ismail, Winkley, & Rabe-Hesk th, 2004; Moss-Morris et al., 
2013; Petrie, Perry, Broadbent, & Weinman, 2012; Safren et al., 2014). These see one’s 
beliefs as the central process in therapy. Subsequently, they employ techniques such as 
verbal modification or behavioral experiments to enable participants to change aberrant 
beliefs about illness, the self, the future or even medication as a means to reduce distress 
or instigate better self-management (Halford & Brown, 2009; Petrie, Cameron, Ellis, 
Buick, & Weinman, 2002; Petrie et al., 2012; Petrie & Weinman, 2012).  
Acceptance and Commitment Therapy is a newer form of cognitive behavioural 
therapy (Hayes, Luoma, Bond, Masuda, & Lillis, 2006). It differs from traditional 
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cognitive therapy in two key ways. First, instead of changing the content of beliefs it 
aims to foster psychological flexibility, which is defined as: being open, aware and in 
contact with the present moment; flexibly engaging in behaviours which facilitate 
overarching life goals (Bond, Hayes, & Barnes-Holmes, 2006). Second, it sees distress 
as a natural consequence of experiencing adversity; and does not explicitly aim to 
reduce distress, but rather to increase one’s ability to undertake valued-activity in its 
presence. ACT uses a range of methods to engender psychological flexibility, for 
example: mindfulness exercises to enable one to be present moment focused; defusion 
exercises to change one’s relationship with thoughts; and, values elicitation exercises to 
orientate participants to valued behaviours (McCracken, 2011).  
Why might ACT have utility in long-term conditions?  
Many have expressed the opinion that ACT has utility over existing 
psychotherapeutic models in the context of long-term conditions (Angiola & Bowen, 
2013; Graham, Simmons, et al., 2014; Hadlandsmyth, White, Nesin, & Greco, 2013; 
Kangas & McDonald, 2011; Karekla & Constantinou, 2010; Low et al., 2012; Moitra, 
Herbert, & Forman, 2011; Whittingham, 2014). For example, negative illness beliefs 
and distress may be realistic in certain conditions at certain times. Thus, ACT’s focus 
on instigating valued behaviours while accepting such thoughts and feelings may prove 
more effective than attempts to directly alter them (as per traditional cognitive therapy) 
(Graham, Simmons, et al., 2014; Low et al., 2012). Others have suggested that non-
adherence to HIV (Moitra et al., 2011) or diabetes (Hadlandsmyth et al., 2013) 
medication are related to avoidance of disease-related thoughts and feelings, such as 
fear or shame. Therefore, ACT’s focus on encouraging (experiential) acceptance in the 
service of meaningful behaviour may be particularly efficacious for disease self-
management. Subsequently, there is emerging evidence that ACT techniques are being 
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adopted by clinical health professionals working with long-term conditions (Thewes et 
al., 2014).  
The present review 
The empirical status of ACT for chronic pain (Veehof, Oskam, Schreurs, & 
Bohlmeijer, 2011) and general mental health populations (A-Tjak et al., 2015; Öst, 
2008; Swain, Hancock, Hainsworth, & Bowman, 2013; Zum & Emmelkamp, 2009) has 
been previously reported. While some reviews have included a very small number of 
studies with long-term conditions (A-Tjak et al., 2015; Gundy, Woidneck, Pratt, 
Christian, & Twohig, 2011; Öst, 2008, 2014), comprehensive review of ACT as applied 
to long-term conditions is lacking. Given the evidenc  of ACT’s existing clinical usage 
in this context (Thewes et al., 2014), calls for further application (Angiola & Bowen, 
2013; Graham, Simmons, et al., 2014; Hadlandsmyth et al., 2013; Kangas & McDonald, 
2011; Karekla & Constantinou, 2010; Low et al., 201; Whittingham, 2014), and the 
rapid rate of growth in ACT intervention studies (Öst, 2014), we present a timely 
review of ACT for long-term conditions. The aim was to collate all ACT applications, 
to accurately describe the field. Case studies were included since they give clinically-
useful descriptive accounts and allow further insight nto the range of applications. It 
has been suggested that the general quality of ACT intervention studies is low 
(Hofmann & Asmundson, 2008; Öst, 2008; Ost, 2014), and that ACT has limited 
additional value over traditional methods (Hofmann & Asmundson, 2008). Therefore, 
we sought to evaluate the quality of studies which use trial methodology; comment on 
the emerging efficacy of ACT applications; and, suggest ways to improve the quality of 





The procedures of this systematic review were informed by accepted guidelines 
for systematic reviewing  (Khan, Ter Riet, Glanville, Sowden, & Kleijnen, 2001; 
Moher, Liberati, Tetzlaff, Altman, & The, 2009). Ovid MEDLINE, EMBASE and 
Psych Info were systematically searched from their earliest available listing to 22nd 
February 2015. Due to the large number of possible long-term conditions, a broad 
search strategy was applied. This used the key terms ACCEPTANCE AND 
COMMITMENT THERAPY and CONTEXTUTAL COGNITIVE BEHAVIO$. 
Abstracts were examined if the title suggested an intervention study with long-term 
conditions. To identify further relevant studies: 1) the reference sections of the included 
studies were examined; 2) Google Scholar was then us d to search amongst articles 
which had cited the included studies. 
Studies were included if they described an ACT intervention applied to a long-
term condition. They were excluded if they: 1) were not published in English; 2) 
described a hypothetical intervention; 3) did not clearly use ACT techniques; 4) were 
undertaken with a chronic pain (since this is well r viewed elsewhere [(McCracken & 
Eccleston, 2003; Veehof et al., 2011)]), or mental health population (including insomnia 
and conversion disorders, ‘functional’ illness etc); 5) were designed to prevent illness in 
a group without a long-term condition (see Figure 1). 
Study quality was then assessed using the Psychotherapy Outcome Study 
Methodology Rating Form (POMRF)(Öst, 2008). This 22-item measure comprises 
various indicators of methodological quality, for example: length of follow-up 
assessment, composition of comparison interventions, reliability and specificity of 
measures, study design, therapist training and supervision. Items are rated as ’Poor’ (0 
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points), ‘Fair’ (1 point) or ‘Good’ (2 points), giving a maximum score of 44 points. Two 
items which appeared to be related to certainty of psychiatric diagnoses were removed. 
Therefore, in the present study, the maximum possible core was 40.  
The quality of all studies was assessed by the lead author (CDG). To improve 
the accuracy/validity of this assessment, a sub-section (5 papers) were randomly 
selected (random number generator) and also rated by another researcher with 
qualification to PhD level (CK). A moderate level of inter-rater agreement between 
reviewers was observed (k = 0.60, p <. 001) (Altman, 1991). Discrepancies were 
discussed and reconciled; then all articles were rated gain by the lead author.  
Data extraction plan 
Data regarding the sample characteristics, composition of the intervention and 
control intervention, outcome measures and indicators of efficacy (proportion of 
statistically significant outcomes and effect size [Cohen’s d]) were extracted. Where 
possible the effect sizes which were reported within an included publication were used. 
If these were not available then effect sizes were calculated via comparison of the post-
intervention scores of the experimental and control g up (between-groups), or 
comparison between pre- and post-intervention score (within-groups).  
 
RESULTS 
The initial database search returned 1436 studies, from which 23 publications 
were retrieved in full. The removal of study protocols and interventions with insomnia 
populations left 15 remaining studies. Four additional studies were obtained from 
Google Scholar. However, upon closer inspection, a study which showed low fidelity to 
ACT, and another with a healthy population were removed. Thus 17 studies were 




Figure 1. Flowchart showing the process of selecting studies included in the review. 
 
Identification of potentially relevant studies (title and 
abstract) by searching of electronic databases  
EMBASE, Ovid MEDLINE® , PsycINFO®.  
n  = 1436 
Exclusion of irrelevant citations mainly ACT 
interventions with in mental health populations or 
non-intervention studies 
n = 1413 
 
  
Retrieval of article in full for potentially relevant 
studies.               
n = 23 
Remaining studies appear consistent with criteria: 
ACT interventions in long-term conditions 
n = 19 
Exclusion of intervention protocols or mediation 
analysis studies 
n = 6 
Exclusion of ACT intervention studies with 
insomnia populations  
n =2 
 
Studies included in the review. 
n = 17 
Articles retrieved from reference 
sections of included articles and 
Google Scholar citations 
n = 4 
Exclusion of an intervention with poor ACT 
fidelity and another targeting prevention of 
illness in a healthy population    
n = 2 
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Description of the included studies 
Of these 17 studies: six were case studies (or case series) (Gillanders & 
Gillanders, 2014; Graham, Gillanders, Stuart, & Gouick, 2014; Masuda, Cohen, 
Wicksell, Kemani, & Johnson, 2011; Moitra et al., 2011; Nes et al., 2012; Skinta, 
Lezama, Wells, & Dilley, 2014); three used pre-post designs with no control group 
(Burke et al., 2014; Feros, Lane, Ciarrochi, & Blackledge, 2013; Goodwin, Forman, 
Herbert, Butryn, & Ledley, 2011); and, eight were randomised controlled trials (RCT) 
(Brown, Whittingham, Boyd, McKinlay, & Sofronoff, 2014; Gregg, Callaghan, Hayes, 
& Glenn-Lawson, 2007; Hawkes, Pakenham, Chambers, Patrao, & Courneya, 2014; 
Hawkes et al., 2013; Lundgren, Dahl, Melin, & Kies, 2006; Lundgren, Dahl, Yardi, & 
Melin, 2008; Nordin & Rorsman, 2012; Rost, Wilson, Buchanan, Hildebrandt, & 
Mutch, 2012; Whittingham, Sanders, McKinlay, & Boyd, 2014). The studies using RCT 
and pre-post designs involved samples of people with: cancer (Feros et al., 2013;  
Hawkes et al., 2014; Hawkes et al., 2013; Rost et al., 2012),  epilepsy (Lundgren et al., 
2006; Lundgren et al., 2008), multiple sclerosis (Nordin & Rorsman, 2012), cardiac 
disease (Goodwin et al., 2011), type II diabetes (Gregg et al., 2007);and, paediatric 
cerebral palsy (Whittingham et al., 2014), brain injury (Brown et al., 2014), and life 
threatening illness (Burke et al., 2014). The RCT studies compared ACT to a waitlist 
control group (Whittingham et al., 2014), treatment as usual (TAU) (Brown et al., 2014; 
Hawkes et al., 2014; Hawkes et al., 2013), and other active treatments (including 
education, yoga, cognitive therapy, relaxation training, supportive therapy) (Gregg et 
al., 2007; Lundgren et al., 2006; Lundgren et al., 2008; Nordin & Rorsman, 2012; Rost 
et al., 2012; Whittingham et al., 2014). In studies using group-based analyses, one study 
had a sample size of 205 (Hawkes et al., 2014; Hawkes et al., 2013); however, most 
others had a small sample size (M = 23.00, SD = 13.03; range = 10 - 45) (Table 2.1 & 
2.2). 
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Most (eight) of the included interventions were delivered at least in part within 
groups (Brown et al., 2014; Burke et al., 2014; Goodwin et al., 2011; Gregg et al., 2007; 
Lundgren et al., 2006; Lundgren et al., 2008; Nordin & Rorsman, 2012; Whittingham et 
al., 2014); with just three (Feros et al., 2013; Hawkes et al., 2014; Hawkes et al., 2013; 
Rost et al., 2012) delivered exclusively via one-to-one sessions with a therapist. The 
number of sessions ranged from 1-12. Most interventions were brief (M = 7 sessions, 
SD = 3.84), with six studies evaluating interventions f no more than 5 sessions (Burke 
et al., 2014; Goodwin et al., 2011; Gregg et al., 2007; Lundgren et al., 2006; Lundgren 
et al., 2008; Nordin & Rorsman, 2012). Participant drop-out from the included 
interventions was low with an average of 81.60% (SD 15.51; range 60 -100) of 
participants completing treatment. Three interventions showed 100% completion 
(Gregg et al., 2007; Lundgren et al., 2006; Lundgren et al., 2008) (Table 2.1.) 
The case studies included a range of long-term conditi s: HIV (Moitra et al., 
2011; Skinta et al., 2014), diabetes (Nes et al., 2012), multiple sclerosis (Gillanders & 
Gillanders, 2014), stroke (Graham, Gillanders, et al., 2014) and sickle cell disease 
(Masuda et al., 2011). No included case study used an experimental design, one 
recorded reliable change (Gillanders & Gillanders, 2014), and one used session-by-































































Child behaviour & 
emotional problems  
(distress) (ECBI; 
SDQ) 
(d = 0.84) 3/3 significant 
(d = 0.67) 
2/3 
maintained 
     
 
    Dysfunctional 
parenting style (PS) 
(d = 0.61) 2/2 significant 
(d = 0.65) 
2/2 
maintained 












Group therapy 5 (7.5) 11 (73%) - Parental distress 
(PCL-C; PECI) 
5/5 significant 
 (d = 1.12) 
- 5/5 
maintained 
     
 
    Psychological 
flexibility (PPF) 
2/3 significant 
(d = 0.72) 
- 3/3 
maintained 
     
 
    Mindfulness 
(MAAS) 
1/1 significant 
(d = 0.54) 
- 1/1 
maintained 






Cancer QoL and 
distress 
Individual therapy 9 (6.75) 45 (62%) - Distress (DT; 
DASS) 
2/2 significant 
(d = 1.05) 
- 2/2 
maintained 
     
 
    QoL (FACT) 1/1 significant 
(d = 0.56) 
- 1/1 
maintained 
     
 
    Psychological 
flexibility (AAQ II) 
1/1 significant 













Group therapy 4 (6) 16 (75%) - Self-report diet 
(ASA-24) 
3/3 significant 
(d = 1.27) 
- - 
         Weight (BMI; lbs) 1/2 significant 
(d = 0.11) 
- - 
     
 
    Self-report exercise 
(IPAQ) 
0/1 significant 
(d = 0.54) 
- - 
     
 
    Mindfulness 
(PHLMS) 
1/2 significant 
(d = 0.31) 
- - 
         Defusion (DDS) 0/1 significant 
(d = 0.23) 
- - 
         Values (VGCM) 1/1 significant 
(d = 0.33) 
- - 
         Psych. flexibility 
(FAAQ; PA-AAQ) 
1/2 significant 
















































Group therapy 1 (4) 43 (100%) Education 
(7hr 
workshop) 





(d = 0.61) 
- 
     
 
    HbA1c 1/1 significant 
(d = 0.42) 
0/1 significant 
(d = 0.35) 
- 
     
 
    Self-management 
(DSCAM) 
1/1 significant 
(d = 1.06) 
1/1 significant 
(d = 0.68) 
- 
         Psychological 
flexibility (AADQ) 
1/1 significant 
(d = 0.49) 
1/1 significant 
(d = 0.78) 
- 
         Understanding 
(DCP) 
1/1 significant 
(d = 0.37) 
0/1 significant 
















(d = 0.14) 
0/3 significant 




     
 
    Self-report weight 
(BMI) 
1/1 significant 
(d = 0.37) 
1/1 significant 
(d = 0.23) 
1/1 
maintained 
     
 





(d = 0.20)  
2/6 
maintained 
     
 
    Distress (BSI-18) 1/1 significant 
- 
0/1 significant 
(d = 0.01)  
0/1 
maintained 
     
 





(d = 0.08)  
0/3 
maintained 
         Psychological 




(d = 0.15)  
0/1 
maintained 





(d = -0.01)  
0/1 
maintained 
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(d = 1.21) 1/1 significant 
(d = 1.45) 
1/1  
maintained 
     
 
    QoL (WHOQOL-
BREF) 
(d = 0.62) 0/1 significant 




     
 
    Life satisfaction 
(SWLS) 
(d = 0.73) 1/1 significant 




















     
 
    QoL (WHOQOL-
BREF) 
1/1 significant 
(d = 0.81 ) 
0/1 in favour 
of yoga 






     
 
    Life satisfaction 
(SWLS) 
0/1 significant 
(d = 0.55 ) 
0/1 significant 
























    
 
    Psychological 
flexibility (AAQ) 












































Rost et al., 
(2011) 




Individual therapy 12 (12) 25 (60%) Cognitive 
therapy 
(12hrs) 
QoL (FACT) 1/1 significant 
(d = 1.59) 
1/1 significant 
(d = 1.35) 
- 
         Distress (POMS; 
BAI; BDI II) 
3/3 significant 
(d = 1.87) 
3/3 significant 
(d = 1.28) 
- 
     
 
    Acceptance coping 
(COPE) 
1/1 significant 
(d = 1.58) 
1/1 significant 
(d = 2.02) 
- 
     
 




(d = - 1.83) 
1/1 significant 
(d = -3.49) 
- 
         Emotional control 
(CECS) 
1/1 significant 
(d = -3.76) 
1/1 significant 
(d = -6.11) 
- 
         Thought 
suppression (WBSI) 
1/1 significant 
(d = -1.97) 
1/1 significant 
(d = -3.02) 
- 
Whittingha
m et al., 
(2014) 















Child behaviour & 
emotional problems 
(ECBI; SDQ) 
 (d = 0.25) 1.3/8 
significant  
(d = 0.48) 
2. 1/8 
significant + 
1 in favour of 
SSTP 




     
 
    Dysfunctional 
parenting style (PS) 
(d = 0.77) 1.2/3 
significant  
(d = 0.82) 
2. 0/3 
significant  













Table 2.1. Footnotes.  
AADQ = Acceptance and Action Diabetes Questionnaire; AAQ II = Acceptance and Avoidance Questionnaire II; ASA-24 = Automated Self-Administered 24-hr 
Dietary Recall; BAI = Beck Anxiety Inventory; BDI =Beck Depression Inventory; BDI II = Beck Depression Inventory II; BMI= Body Mass Index; BSI-18= Brief 
Symptom Inventory (18 item); CCVFFQ = Cancer Council Victoria Food Frequency Questionnaire; CECS = Courtland Emotional Control Scale; COPE = The COPE 
Questionnaire; DASS = Depression Anxiety and Stress Scale; DCP = Diabetes Care Profile; DSCAM = Diabetes Self Care Assessment Measure; DT = Distress 
Thermometer; ECBI = Eyberg Child Behavior Inventory; FAAQ = Food Acceptance and Action Questionnaire; FACITFS = Functional Assessment of Chronic Illness 
Therapy Fatigue Scale; FACIT-Sp = Functional Assessm nt of Chronic Illness Spiritual Well-being; FACT = Functional Assessment of Cancer Therapy; GLTEQ = 
Godin Leisure-Time Exercise Questionnaire; HADS = Hospital Anxiety and Depression Questionnaire; IPAQ = International Physical Activity Questionnaire; MAAS 
= Mindfulness Attention Awareness Scale; PA-AAQ = Physical Activity Acceptance and Action Questionnaire; PCL-C = PTSD Checklist-Civilian Version; PECI = 
Parent Experience of Child Illness; PGI = Post-traum tic Growth Inventory; PHLMS = Philadelphia Mindfulness Scale; POMS = Profile of Mood States; PPF = 
Parental Psychological Flexibility Questionnaire; SDQ = Strengths and Difficulties Questionnaire; SF-36 = Short-Form 36; SI = Seizure Index; SWLS = Satisf ction 




*Large number of outcome variables; only those which appeared to be primary and secondary outcomes reported (post-traumatic growth, spirituality and fatigue excluded) 












Study Population N Target of the 
intervention  











and with partner 







exercises also used.  
Clinically significant 
improvements in depression 
and anxiety (HADs) – 
considered ‘recovered’ at the 
end of treatment. 
Improvement in 




al., (2015)  







Mindfulness (contact with 
the present moment; self 




Substantial improvements in 
anxiety and stress across the 
course of treatment. Smaller 
improvement in depression. 
Substantial improvement in 



















Improvement to follow-up in 
child’s self-rated and parent 
rated functioning. 
Improvement in average pain 
levels. Improvement in QoL 
at follow-up. Improvement in 
psychological flexibility and 
in parent’s acceptance of 
child’s illness.  










Exploring willingness to 
accept HIV diagnosis, 
fusion with HIV fears, 
experiential avoidance of 
HIV self-management. 
Mindfulness, values and 
committed action 
explored in relation to 
adherence. 
Trends towards improvement 
in viral load. The majority of 
participants reported that the 
intervention was helpful. 












Unclear  Identifying values and 
valued activities in the 
context of diabetes self-
management.  
A small change in HBA1c was 
noted as well as improvements 
in QoL, diabetes-related distress 
and BMI. Generally patients 
reported being satisfied with the 
intervention.  
Skinta et al., 
(2014) 





Stigma and experiential 
avoidance; valued-living 
and committed action; 
acceptance and 
mindfulness (self-as-
context); willingness.  
Improvements in HIV self-
stigma which were maintained 
at two month follow-up. Some 
evidence of improvement in 
psychological flexibility 
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Table 2.3. Between-group standardised and unstandardised effect sizes (with 95% 
confidence interval), for each variable. 
Study Outcomes 
(Measures) 
Improvement compared to control – ES and (95%CI) 
for each measure* 
Brown et 
al., (2014) 
Child behaviour & 
emotional problems  
(distress) (ECBI; 
SDQ) 
3/3 significant (mean d = 0.67) 
-ECBI intensity  0.90 (0.34, 1.46) 
-ECBI problem  0.76 (0.20, 1.31) 
-SDQ 0.50 (-0.04, 1.05) 
 Dysfunctional 
parenting style (PS) 
2/2 significant (mean d = 0.65) 
- Laxness 0.76 (0.21, 1.32) 
- Over-reactivity 0.54 (-0.01, 1.08) 
Gregg et al., 
(2007) 
No. in glucose 
control 
1/1 significant  
0.61* 
 HbA1c 0/1 significant  


















0/3 significant  (d = 0.06) 
- moderate 0.10 (-0.11, 0.32); 16.5 mins (-7.4, 40.5) 
- vigorous - 0.05 (-0.26, 0.16); -2.7 mins (-14.2, 8.9) 
- mod-vig  0.11 (-0.10, 0.31); 11.5 mins (-18.82, 41.9) 
 Self-report weight 
(BMI) 
1/1 significant 
d = 0.23 (0.02, 0.44); -0.5 BMI (-1.0, 0.0) 
 Self-report diet 
(CCVFFQ) 
3/6 significant (d = 0.20)  
- Fat 0.37 (0.16, 0.59); % fat  -8.5 (-13.4, 3.6) 
- Sat fat  0.33 (0.12, 0.55); % sat fat -3.5 (-5.7, 1.2) 
- Fibre -0.10 (-0.31, 0.11); g/day -0.7 (-2.2, 0.8) 
- Fruit  0.15 (-0.06, 0.36); servings 0.2 (-0.0, 0.4) 
- Veg 0.30 (0.09, 0.52); servings 0.4 (0.2, 0.7) 
- Alcohol 0.12 (-0.09, 0.33); units -1.4 (-3.7, 1.0) 
 Distress (BSI-18) 0/1 significant 
d = 0.01 (-0.20, 0.22)  
 QoL (SF-36; 
FACT-C) 
0/3 significant 
(d = 0.08)  
-PCS 0.0 (-0.21, 0.21) 
-MCS 0.09 (-0.12, 0.30) 
-FACT-C QoL 0.15 (-0.06, 0.36) 
 Psychological 
flexibility (AAQ II) 
1/1 significant 




d = 0.00- 
Lundgren et 
al., (2006) 
Seizure index (SI) 1/1 significant† 




d = 0.37 (-0.40, 1.13) 
 Life satisfaction 
(SWLS) 
1/1 significant 
(d = 1.72)* 
1.77 (0.89, 2.67) 
Lundgren et 
al., (2008) 
Seizure index (SI) 1/1 significant 
d =1.14 (0.14, 2.14) 
 QoL (WHOQOL-
BREF) 
0/1 in favour of yoga 
d = -0.38 (-1.32, 0.56) 
 Life satisfaction 
(SWLS) 
0/1 significant 










Rost et al., 
(2011) 
QoL (FACT) 1/1 significant 
d = 1.01(0.27, 1.77) † 
 Distress (POMS; 
BAI; BDI II) 
3/3 significant† 
(d = 1.28)* 
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Distress 1.34 (0.56, 2.12) 
Depression 0.86 (0.12, 1.59) 
Anxiety 1.20 (0.44, 1.97) 
 Acceptance coping 
(COPE) 
1/1 significant* 





9.90 (7.34, 12.46) 
 Emotional control 
(CECS) 
1/1 significant* 




1.94 (1.08, 2.79) 
Whittingha
m et al., 
(2014) 





(d = 0.48) 
-ECBI Intensity  0.77 (0.17, 1.38) 
-ECBI Problem  1.34 (0.68, 1.98) 
-SDQ Emot sympts 0.37 (-0.22, 0.96) 
-SDQ Conduct probs 0.25 (-0.34, 0.84) 
-SDQ Hyperactivity 0.22 (-0.37, 0.80) 
-SDQ Peer Probs 0.47 (-0.12, 1.07) 
-SDQ Prosocial 0.10 (-0.49, 0.68) 
-SDQ Impact  0.30 (-0.29, 0.89) 
2. 1/8 
significant + 
1 in favour of SSTP 
(d = 0.14) 
-ECBI Intensity  0.43 (-0.16, 1.02) 
-ECBI Problem  0.58 (-0.02, 1.17) 
-SDQ Emot sympts  -0.41 (-1.0, 0.18) 
-SDQ Conduct probs  -0.18 (-0.76, 0.41) 
-SDQ Hyperactivity 0.11 (-0.47, 0.70) 
-SDQ Peer Probs-0.32 (-0.91, 0.26) 
-SDQ Prosocial 0.29 (-0.30, 0.88) 
-SDQ Impact  0.65 (0.06, 1.26) 
 Dysfunctional 
parenting style (PS) 
1.2/3 
significant  
(d = 0.82) 
-PS Laxness 0.43 (-0.16, 1.03) 
-PS Over reactivity 1.11 (0.48, 1.76) 
-PS Verbosity 0.93 (0.31, 1.54) 
2. 0/3 
significant  
(d = 0.39) 
-PS Laxness 0.06 (-0.53, 0.64) 
-PS Over reactivity 0.66 (0.06, 1.26) 
-PS Verbosity 0.44 (-0.15, 1.04) 
 
 
†ES calculation differs from that published in paper, to enable calculation of 95% CI  




Quality of the studies using group-based statistics 
Study quality (excluding case studies) was generally quite low (M = 19.82, SD = 
5.38; range = 10-30) with just 6 of the 11 (Brown et al., 2014; Gregg et al., 2007; 
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Hawkes et al., 2014; Hawkes et al., 2013; Lundgren et al., 2006; Lundgren et al., 2008; 
Whittingham et al., 2014) studies receiving more than alf of the available points on the 
POMRF. We used this cut-off (>20 points on the POMRF) to denote a higher-quality 
study. The highest quality study (Hawkes et al., 2014; Hawkes et al., 2013) achieved a 
score of 30 (Table 2.2 and Appendix vi). 
Several consistent strengths were apparent across studies. For example, all 
studies showed a fair description of statistical methods and presentation of results, with 
all but one (Nordin & Rorsman, 2012) achieving a maxi um score. All studies gave at 
least a fair description of the intervention and/or were able to direct readers to an 
intervention manual, with 6 of 11 (Brown et al., 2014; Gregg et al., 2007; Lundgren et 
al., 2006; Lundgren et al., 2008; Nordin & Rorsman, 2012; Whittingham, 2014) 
achieving a maximum score. All studies used outcomes asures that were 
psychometrically adequate (specific and/or reliable), and all included a population 
which appeared adequately representative of a clinica  sample.  
Nonetheless, only one study used trial evaluators who ere blinded to the 
treatment condition (Hawkes et al., 2014; Hawkes et al., 2013). Also, just one 
(Lundgren et al., 2006) showed  a clear effort to control for concomitant treatments. 
Studies often introduced a systematic condition/therapist confound by having one 
therapist per condition or did not report the number of therapists (Burke et al., 2014; 
Feros et al., 2013; Lundgren et al., 2008; Rost et al., 2012). Just three studies (Gregg et 
al., 2007; Hawkes et al., 2014; Hawkes et al., 2013; Whittingham et al., 2014) included 
an a priori power/sample size calculation; while consideration of clinical significance 
was apparent in just four studies (Feros et al., 2013; Gregg et al., 2007; Hawkes et al., 
2014; Hawkes et al., 2013; Whittingham et al., 2014). Where control interventions were 
included these were frequently unequal in duration to the ACT intervention (evident in 
4 of 6 RCTs) (Brown et al., 2014; Gregg et al., 2007; Hawkes et al., 2014; Hawkes et 
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al., 2013; Whittingham et al., 2014). Long-term (i.e. 12 month) follow-up was evident 
in just three studies (Hawkes et al., 2014; Hawkes et al., 2013; Lundgren et al., 2006; 
Lundgren et al., 2008). 
Applications and their emerging efficacy 
The returned ACT interventions sought to engender change in a range of 
outcomes. An analysis of the emerging efficacy for ACT in each outcome is described 
below.  
Distress 
Five studies evaluated whether ACT interventions can reduce distress in people 
with long-term conditions (Burke et al., 2014; Feros et al., 2013; Hawkes et al., 2014; 
Hawkes et al., 2013; Nordin & Rorsman, 2012; Rost et al., 2012). With one exception 
(Nordin & Rorsman, 2012), all observed a significant improvement in most measures of 
distress following ACT. Where reported, this change showed a large effect size (range d 
= 1.05 – 1.86) (Burke et al., 2014; Feros et al., 2013; Rost et al., 2012). 
Three of these studies used RCT designs (Hawkes et al., 2014; Hawkes et al., 
2013; Nordin & Rorsman, 2012; Rost et al., 2012). The highest quality study compared 
a telephone-delivered ACT intervention for people with colorectal cancer to TAU 
(Hawkes et al., 2014; Hawkes et al., 2013).  Here, no significantly greater improvement 
was observed in the ACT group compared to TAU at pos -intervention (d =-0.01) or 
follow-up. However, distress could be considered a secondary outcome in this 
intervention which primarily sought to improve lifestyle (diet and weight). Accordingly, 
participants were not included based on a high level of distress, making it less likely 
that a post-intervention improvement in this outcome ight be detected. 
Two lower-quality studies, with interventions more explicitly targeting distress, 
compared ACT to active treatments (relaxation training (Nordin & Rorsman, 2012)] and 
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cognitive therapy (Rost et al., 2012)]). Rost et al., (2012) evaluated a 12-session ACT 
treatment, delivered in a one-to-one format, for women with late-stage ovarian cancer. 
A significantly greater reduction occurred in all measures of distress following ACT 
when compared to cognitive therapy, and a very large verage effect size was observed 
for this comparison (d = 1.28); however, the 95% confidence intervals surrounding the 
constituent effect sizes were quite broad, and also included very trivial effect sizes (see 
Table 2.3). This suggests little precision in this estimate, and that the ‘true’ effect size 
might be much smaller than this mean value. Nordin & Rorsman, (2012) evaluated a 
brief group-delivered ACT intervention for distress in multiple sclerosis. There was no 
significant benefit of ACT over relaxation training post-intervention or at follow-up. 
However, this trial appeared severely underpowered, with just 11 participants beginning 
the ACT condition.  
Two case studies detail ACT applied to distress in neurological illnesses 
(Gillanders & Gillanders, 2014; Graham, Gillanders, et al., 2014). Gillanders & 
Gillanders (2014) describe an intervention involving an individual with multiple 
sclerosis and their partner; sessions were aimed at a justment to progressing multiple 
sclerosis, against a background of childhood trauma. The case study showed clinically 
significant improvements in psychological flexibility and distress. Graham, Gillanders 
et al., (2015) outline the application of an ACT intervention to post-stroke anxiety – 
detailing how acceptance, workability analysis and present-moment-awareness can be 
used to manage illness-related fears. Subsequent improvements in stress and post-stroke 
anxiety were noted in this study. 
 
Summary 
With one exception (Nordin & Rorsman, 2012), ACT interventions were 
consistently associated with post-intervention improvements in distress. However, bar 
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one highly-supportive but lower-quality study (Rost et al., 2012), there is little evidence 
to suggest that ACT is superior to TAU or other psychological interventions, or that the 
consistent post-intervention improvements observed ar  little more than regression to 
the mean, placebo or the result of non-specific effects of therapy.  
Parenting of children with long-term conditions 
              Two higher quality studies evaluated ACT for improving the parenting, and 
subsequent emotional and behavioural problems, of children with brain injury (Brown 
et al., 2014) and cerebral palsy (Whittingham et al., 2014) respectively. Both studies 
included an ACT-enhanced version of an established parenting program (Stepping 
Stones Triple P (Sanders, 2012)]), and had similar sample sizes (N = 30 (Brown et al., 
2014)] and N = 23 (Whittingham et al., 2014)]). Following the intervention both 
observed a moderate (d = 0.61 – d = 0.77) improvement in parenting. With one (Brown 
et al., 2014) noting a large and statistically signif cant (d = 0.84) subsequent 
improvement in child behavioural and emotional problems; while the other observed a 
small change (d = 0.25)  in this outcome.                                    When compared to 
waitlist control or TAU, both observed significant improvements of moderate-to large 
size (d = 0.65 – 0.82) in dysfunctional parenting styles po t intervention; with most 
measures showing statistically significant improvements; withthe 95% confidence 
intervals including small to large effect sizes . However, while a subsequent impact on 
child behavioural and emotional problems in favour f ACT was evident in these 
comparisons, they showed slightly smaller effect size  (d = 0.48 – 0.67), with 95% 
confidence intervals ranging from negative values to large effect sizes depending on the 
domain (Table 2.3).  
Whittingham et al., (2014), included a further trial arm: comparing the ACT 
enhanced Stepping Stones Triple P intervention to the Stepping Stones Triple P 
intervention alone. Here, just 1 of 8 child behavioural and emotional problems variables 
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showed greater response to ACT, with one showing a si nificantly greater response to 
Stepping Stones Triple P alone. However, on average, a small effect size (d = 0.14) in 
favour of ACT was noted. No post intervention between-group differences in 
dysfunctional parenting were apparent, but at six-month follow-up the ACT group had 
significantly better outcomes on 2 of 3 measures. However, it was notable that the 
ACT-embedded intervention was 4 hours longer than te Stepping Stones Triple P 
alone. Therefore, these differential outcomes may be related to differences in 
intensity/dosage.  
Masuda et al., (2011) present a detailed case study of a family-based ACT 
intervention for improving functioning in a teenager with sickle cell disease. A range of 
ACT techniques were applied: perspective-taking, experiential acceptance, mindfulness 
and values-clarification in relation to parenting. Post-intervention improvements were 
noted in child- and parent-reported outcomes (such as functioning and parental 
acceptance of their child’s illness) at the end of the intervention, with further 
improvement to three-month follow-up. 
Summary  
Two higher-quality studies support the application of ACT interventions to 
improving the parenting of children with long-term conditions. ACT showed effects 
which were greater than TAU for improving dysfunctional parenting. Further, results 
from one high-quality study (Whittingham et al., 2014) suggest that incorporating ACT 
into an established parenting intervention may significantly increase its efficacy for 
parenting and possibly children’s emotional regulation or behaviour. Therefore ACT 
components appeared to add value to an established par nting treatment. However, a 
caveat is that the ACT-embedded intervention was slightly longer in duration than the 
established parenting intervention alone, and differential outcomes may be explained by 
this; thus, better controlled studies are required. 
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Self-management/lifestyle 
Three studies evaluated ACT for improving disease self-management and/or 
lifestyle (Goodwin et al., 2011; Gregg et al., 2007; Hawkes et al., 2014; Hawkes et al., 
2013). In a lower-quality study Goodwin et al., (201 ) evaluated a brief group-based 
ACT intervention for improving lifestyle in people with cardiac diseases. This pre-post 
design observed significant and large improvements in all aspects of self-reported diet 
(3 of 3 measures significant; d = 1.27), and small, less consistent improvements in 
weight (1 of 2 measures significant; d = .11). While there was no significant 
improvement in self-reported exercise (0 of 1 measures significant), a moderate effect 
size was observed for this comparison (d = 0.54).  
In a higher-quality study, Hawkes et al., (2013, 2014) assessed a more intensive 
intervention (individual sessions, more sessions) for improving lifestyle in colorectal 
cancer survivors. Similarly, significant improvements were seen in self-reported weight 
(1 of 1 measures significant) and most aspects of diet (4 of 6 measures significant). 
Compared to a TAU condition in which educational materi ls regarding methods to 
reduce cancer risk were made available, significant improvements were observed in 
self-reported weight and diet, and these were mostly maintained at 12 month follow-up. 
However, this study had a very large sample size (N = 205) and while most were 
statistically significant, these changes showed a sm ll effect size (d = 0.20 – 0.23), with 
most 95% confidence intervals also lying within thesmall effect size range (Table 2.3). 
No improvements in self-rated physical activity over TAU were apparent at post-
intervention (0 of 3 measures significant, d =0.06); however, by 12 month follow-up the 
ACT group were significantly more active (2 of 3 measures significant).  
In another high-quality study, Gregg et al., (2007) evaluated an ACT-based 
diabetes self-management workshop. Compared to a diabetes education group, they 
observed a significant improvement of moderate size in self-management (d = .68), and 
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subsequently, a significantly greater proportion were in objectively measured glucose 
control (d = 0.61). However, the 95% confidence intervals suggest little precision in the 
effect size estimates (Table 2.3), and  no significant difference between groups in mean 
HbA1c blood levels was apparent (d = 0.35).  
One case series describes a smartphone-based intervention for improving self-
management in diabetes (Nes et al., 2012). The smartphones included diaries with 
written situational feedback, alongside face-to-face nd telephone consultation with 
clinicians. The intervention was experienced as acceptable and few technical problems 
were encountered.  
Summary 
There is emerging evidence that ACT can improve disase self-management and 
life-style. One higher-quality study showed support when compared to TAU, though the 
size of this effect appeared very small (Hawkes et al., 2014; Hawkes et al., 2013)  and 
many outcomes were self-reported. In another higher-quality study a significant 
improvement of moderate size was observed in biochemical measures of disease self-
management. Thus, at present, a small number of studie  suggest that ACT may be 
effective in these contexts. However, given that so few comparisons could be made (one 
comparison with TAU; one comparison with an active reatment) this evidence is very 
preliminary.  
Quality of Life (QoL) 
Five studies included QoL as an outcome measure (Feos et al., 2013; Hawkes et 
al., 2014; Hawkes et al., 2013; Lundgren et al., 2006; Lundgren et al., 2008; Rost et al., 
2012). All showed significant improvements in QoL following ACT (Feros et al., 2013; 
Hawkes et al., 2014; Hawkes et al., 2013; Lundgren et al., 2008; Rost et al., 2012); with 
moderate-to-large effect sizes (d = 0.56 to d = 1.59), where these were reported or could 
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be calculated (Feros et al., 2013; Lundgren et al., 2006; Lundgren et al., 2008; Rost et 
al., 2012).  
One higher quality study compared ACT to TAU for improving lifestyle and 
QoL in colorectal cancer survivors (Hawkes et al., 2014; Hawkes et al., 2013). Here no 
significant improvements over TAU were observed in QoL domains (Hawkes et al., 
2014; Hawkes et al., 2013), with a corresponding small average effect size (d = 0.08), 
quite precise 95% confidence intervals suggesting that a small effect size is likely 
(Table 2.3). 
Three studies compared ACT to active treatments (Lundgren et al., 2006; 
Lundgren et al., 2008; Rost et al., 2012). Two were higher-quality, albeit likely slightly 
underpowered, studies investigating the efficacy of the same ACT intervention for 
improving seizure control and QoL in epilepsy (Lundgren et al., 2006; Lundgren et al., 
2008).  When compared to supportive therapy, a small non-significant improvement in 
QoL was observed at post-intervention (d = 0.37, 95% CI -0.40, 1.13)(Lundgren et al., 
2006), which became significant at  one year follow-up (Lundgren et al., 2006). 
However, when compared to yoga, a small effect size was in favour of yoga was 
observed (d = -0.38, 95% CI -1.32, 0.56) (45). One lower-quality study investigated the 
impact of one-to-one ACT sessions on distress and QoL in women with late-stage 
ovarian cancer (Rost et al., 2012). When compared to an intervention of the same 
intensity which was reminiscent of cognitive therapy (involving cognitive restructuring, 
problem-solving, relaxation training), an average large (d = 1.28) significantly greater 
improvement in QoL was apparent in the ACT group; however, estimated  95% 
confidence intervals also included small effect size  (Table 2.3). 
Summary  
The existing evidence presents an inconsistent picture of the efficacy of ACT for 
improving QoL in long-term conditions. While a consistent post-intervention 
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improvement in QoL was apparent, it is unclear whether ACT interventions are more 
effective than TAU or other active treatments, or again if post-intervention 
improvements are the result of placebo or non-specific therapy factors.  
Psychological Flexibility 
Six studies assessed post-ACT intervention changes i  psychological flexibility, 
as measured with the Acceptance and Avoidance Questionnaires (Burke et al., 2014; 
Feros et al., 2013; Goodwin et al., 2011; Gregg et al., 2007; Hawkes et al., 2014; 
Hawkes et al., 2013; Nordin & Rorsman, 2012). All observed significant pre-to-post 
intervention improvements following ACT in at least half included measures of 
psychological flexibility. Where it was reported or could be calculated (Burke et al., 
2014; Feros et al., 2013; Goodwin et al., 2011; Gregg t al., 2007), this change showed 
a small-to-moderate effect size (d =0.57-0.72).  
One study compared changes in psychological flexibility to TAU. This higher-
quality trial of ACT for people with colorectal cancer observed a comparatively greater 
improvement in psychological flexibility in the experimental group (Hawkes et al., 
2014; Hawkes et al., 2013). However, this difference had a very small effect size (d = 
0.15, 95% CI -0.06, 0.36) and it was not maintained at 12 month follow-up.  
Two studies which compared an ACT intervention to active treatments returned 
divergent results. In a higher-quality study, Gregg t al., (2007) evaluated an ACT self-
management workshop for diabetes self-regulation, cmpared to an educational diabetes 
self-management workshop alone. Post-intervention cha ges in psychological flexibility 
were greater in the ACT group, with a moderate effect size (d = 0.78); However, the 
estimated 95% CI of this effect size was very broad, also including trivial effect sizes 
(Table 2.3). A lower-quality evaluation of an ACT intervention for people with multiple 
sclerosis observed no significant improvement compared to relaxation training, since 
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both interventions showed significant improvement by post intervention (Nordin & 
Rorsman, 2012).   
Summary 
Improvements in psychological flexibility following ACT were evident across 
studies. One higher- quality study reported this improvement to be greater than TAU, 
albeit with a very small effect size (Hawkes et al., 2014; Hawkes et al., 2013). Another 
observed greater improvement following ACT when compared to education (Gregg et 
al., 2007); however, a lower-quality study found no evidence of this effect when 
compared to relaxation training, since improvements wa  noted in both interventions 
(Nordin & Rorsman, 2012). Thus, while there are fewstudies, the evidence to date 
suggests that psychological flexibility improvement following ACT may be slightly 
greater than for treatment as usual and there is little to suggest that it is significantly less 
effective than other treatments.  
Symptom Control 
Two higher-quality studies evaluated the efficacy of ACT for directly 
controlling symptoms (Lundgren et al., 2006; Lundgren et al., 2008). Both included the 
same ACT intervention, which comprised sessions teaching behavioural methods for 
improving seizure control (Lundgren et al., 2006; Lundgren et al., 2008). These 
observed significantly greater improvements in seizure severity following ACT, when 
compared to supportive therapy (Lundgren et al., 2006) or yoga (Lundgren et al., 2008); 
with large effect sizes observed for these comparisons (d =1.4-1.45), and estimated 95% 
confidence intervals all lying within the large range (Table 2.3). However, both studies 
were undertaken by the same research group; thus replications by other groups are 
required. It could also be argued that the behavioural seizure control methods were the 
active component here and not ACT.  
Summary 
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With two supportive higher quality studies the evidence supporting the 
application of ACT to seizure control is promising. However, further independent 
replication is required, where the effects of ACT-enhanced seizure control methods can 
be disentangled from those of seizure control methods alone. 
Adherence 
No studies using pre-post- or RCT designs evaluated ACT for improving 
adherence to medication. However, two case series were returned. These demonstrated a 
smartphone-delivered intervention to prompt self-management behaviours (including 
medication adherence) in diabetes (Nes et al., 2012), and the use of acceptance, values 
and committed action exercises to improve adherence to HIV medication (Moitra et al., 
2011). Both interventions were judged as acceptable by participants and post-
intervention trends towards improvements in HIV biomarkers, HBA1C and fasting 
blood glucose were observed.  
Summary  
Two case studies provide example applications of ACT in this context, with 
encouraging changes in outcomes. Therefore, larger-scale evaluations of ACT for 
improving adherence are warranted.  
Stigma 
One case study described an ACT-based group for reducing HIV- related self-
stigma (Skinta et al., 2014). This emphasised the defusion, self-as-context, and values 
aspects of ACT, and some participants showed an improvement in self-stigma across 
sessions. 
Summary 
This further application demonstrates the versatility of the ACT model. 
However, the design enabled no comment on emerging efficacy. 
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DISCUSSION 
A summary of ACT’s use in Long-term conditions 
ACT has been applied across many long-term conditions, for example: cancer 
(Feros et al., 2013; Hawkes et al., 2014; Hawkes et al., 2013; Rost et al., 2012), epilepsy 
(Lundgren et al., 2006; Lundgren et al., 2008), paediatric illness (Brown et al., 2014; 
Burke et al., 2014; Whittingham et al., 2014), cardi c disease (Goodwin et al., 2011), 
multiple sclerosis (Nordin & Rorsman, 2012), and diabetes (Gregg et al., 2007). Here 
ACT has been used to elicit change in a range of outcomes, from improving 
lifestyle/disease self-management (Gregg et al., 2007; Hawkes et al., 2014; Hawkes et 
al., 2013), and symptom control (Lundgren et al., 2006; Lundgren et al., 2008) to 
reducing distress (Nordin & Rorsman, 2012; Rost et al., 2012) and improving QoL 
(Feros et al., 2013; Lundgren et al., 2006; Lundgren et al., 2008). Several case studies 
gave detailed description of the process of applying ACT to distinct clinical problems, 
including: family intervention for functional impairment in an adolescent with sickle 
cell disease (Masuda et al., 2011); couples work for trauma and distress in MS 
(Gillanders & Gillanders, 2014); one-to-one session for post stroke anxiety (Graham, 
Gillanders, et al., 2014); a smart-phone delivered diabetes self-management intervention 
(Nes et al., 2012); and, interventions to improve self- tigma (Skinta et al., 2014) and 
non-adherence in HIV (Moitra et al., 2011). 
The range of long-term conditions and applications demonstrates the flexibility 
of the ACT model and also reflects the extent to which practitioners (Thewes et al., 
2014) and clinical researchers (Angiola & Bowen, 2013; Graham, Simmons, et al., 
2014; Hadlandsmyth et al., 2013; Kangas & McDonald, 2011; Karekla & Constantinou, 
2010; Moitra et al., 2011) working with long-term conditions have embraced ACT. 
Indeed, the number of intervention studies is increasing each year, with almost half the 
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included studies published in 2014 (the year preceding the systematic search). It is 
arguable as to whether the wide-spread adoption of ACT is recognition that it is 
particularly applicable to long-term conditions, or is a therapeutic fad. However, given 
that research in this area is young - the first included ACT intervention study was 
published in 2006 (Lundgren et al., 2006) - time is needed before this can be 
established.   
It has been suggested that ACT might be usefully applied to medication non-
adherence (Hadlandsmyth et al., 2013; Moitra et al., 2011). However, despite promising 
findings in case studies (Moitra et al., 2011; Nes et al., 2012), no comprehensive trials 
of this were evident in the present review. This is a missed opportunity for two reasons: 
1) Non-adherence to medication is a major public healt  problem, with an estimated 30-
50% of medication not taken as recommended, and subseq ent serious repercussions 
(Horne et al., 2005); 2) adherence/non-adherence is a behaviour with a range of 
cognitive-behavioural correlates (Horne & Weinman, 1999); (Daley, Myint, Gray, & 
Deane). Therefore psychological intervention (potentially ACT) should be considered a 
first-line intervention (Petrie et al., 2012; Petri & Weinman, 2012).  
State of the evidence 
It is a consistent finding that ACT is associated with improved outcomes across 
applications within long-term conditions. However, the paucity of studies using RCT 
designs (per application) and the general low quality of studies, meant it was unclear 
whether this was due to the intervention, non-specific therapy factors, placebo effect or 
regression to the mean. Indeed, many studies had very small sample. This is 
problematic because a negative correlation between sample size and effect sizes exists 
(Slavin & Smith, 2009) (Slavin, 2009). Critics believe this to be due to an interaction 
between the large variability of results in underpowered studies, and a publication bias. 
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Meaning that only those with statistically significant results, and thus very large effect 
sizes (given the small sample size) are published. The large proportion of such 
underpowered studies in this review leads one to wonder at the extent to which this 
phenomenon skews our results. Relatedly, the effect sizes of several very positive ACT 
studies (Rost et al., 2012; Gregg et al., 2006) had broad 95% confidence intervals, 
suggesting that the ‘true’ effect size could also lie in the smaller, or even the negative 
ranges. Thus, further higher quality studies are thus required to establish reliable/valid 
effect size estimates. 
Thus, an overall comment on this emerging field of ACT applications is that, 
whilst findings to date are encouraging for some applications, much more high-quality 
research is needed before any application could be considered to have comprehensive 
empirical support  (for example criteria see (Chambless & Hollon, 1998; Öst, 2008, 
2014)) Nonetheless, there is emerging evidence that ACT may be effective in some 
contexts; With supportive higher-quality studies and little convincing counter-evidence, 
ACT shows promising application for improving the parenting of children with chronic 
illness, seizure control in epilepsy, psychological flexibility, and possibly self-
management/lifestyle.  
A further consideration regarding efficacy, is that the included interventions 
tended to have a very low number of sessions. A contemporaneous review of ACT 
interventions applied to anxiety (Swain et al., 2013) found that just 17% of ACT 
interventions were of 5 sessions or less compared to 45.5% in the present review, with 
many included interventions delivered by phone or in groups. The included 
interventions could therefore be considered a ‘low-dosage’ of psychotherapy. Since a 
dose-effect relationship has been noted in psychotherapy, with those receiving more 
sessions having better final outcomes (Kopta, 2003), one might expect a smaller impact 
of ACT within the current context than in mental health. Thus, researchers investigating 
 75
the efficacy of ACT interventions for long-term conditions should consider if they are 
providing interventions which are of sub-optimal inte sity. Since long-term conditions 
are often disabling, life-threatening and can be accompanied by mood disturbance, one 
might reason that high-intensity interventions are required to elicit optimal changes. 
Methodological Suggestions 
The general low-quality of available evidence regarding efficacy is in contrast to 
the apparent clinical adoption of ACT for long-term conditions (Hadlandsmyth et al., 
2013; Kangas & McDonald, 2011; Moitra et al., 2011; Thewes et al., 2014). This 
highlights the need for higher quality investigations of ACT in these contexts. Future 
studies should build on existing methodological strengths in: the presentation of results; 
description of treatment; the use of specific and reliable outcome measures; and the 
inclusion of representative samples. However, considerable improvement in 
methodology is required, with more RCTs needed. Below is a list of ways to improve 
trial methodology based on current limitations.  
 1.) Trained evaluators who are blind to condition allocation should assess study 
variables at each stage of the trial.  
 2.)  Interventions should include at least two therapists per treatment; this is required to 
disentangle the effects of the intervention from the clinician delivering the intervention. 
3.) A priori power calculations are required: several studies appeared underpowered and 
it was unclear to what extent. 
4.) Concomitant treatments (other medications/interventions which might affect mood 
or behaviour) should be clearly described. 
5.) Active control interventions should be clearly described and matched for length, 
intensity, components and clinician allegiance. 
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6.) Non-active control conditions should also be described clearly. In particular, detail 
should be given regarding the composition of TAU contr l conditions. 
7.) Long-term follow-up is required (at least 12 months).  
8.) To comment on impact, a priori indicators of clini al significance should also be 
used, and economic analysis considered.  
9.) When behaviours are outcomes, direct measurement should be included (for 
example, pedometers to record physical activity, and biochemical measures of 
adherence) (Miller & Hays, 2000; Tudor-Locke & Myers, 2001). 
10.) Finally, to aid the post-hoc calculation of effect-sizes, means and standard-
deviations (or standard errors) for pre- and post-intervention measurements should be 
supplied. Further, to allow for alternative methods f calculating the effect size of 
within-group changes, correlation co-efficients between pre- and post- intervention 
variables could be provided as supplementary information (see(Lakens, 2013)for a 
debate on this topic).  
The design of ACT case study research could also be improved. Session-by-
session measurement of outcomes and reliable change in outcomes were rarely reported. 
While case studies are arguably most useful as detailed descriptive accounts of the 
process of applying interventions, this does not mean that evaluation of change in 
outcomes is unimportant. Single case experimental designs can be used (Smith, 2012), 
and tools are available to assess the statistical significance of changes across the period 
of intervention (Borckardt et al., 2008; Morley, 2014), as well as mediation via cross-
lagged correlation (Borckardt et al., 2008). Indeed, in rare illnesses, the highest level of 






Several limitations are implicit in the present review. First, owing to the 
existence of few RCTs per application, a detailed meta-analyses was omitted from the 
present review. However, given the rapid increase in intervention studies with long-term 
conditions, this may soon be recommended.  
A first limitation was the moderate level of inter-rater agreement in classifying 
the quality of the studies, which also indicates substantial disagreement between 
reviewers. This may have occurred for a number of reasons: it may reflect a lack of 
clarity/validity/reliability in the items of the quality assessment measure (POMRF), or 
indeed individual differences between raters (different training backgrounds, or 
individual differences in understanding of the texts/items). To enable more simple 
quantification and communication of the quality of studies in relation to their findings, a 
dichotomous cut-off for classifying studies as higher-quality and lower-quality was 
used. This division could be considered somewhat arbi r y, and we would thus 
encourage readers to also reflect on individual quaity r tings of each study (Table 1; 
Appendix vi) in conjunction with the findings of the review. A recent review used z-
scores (>1  = high quality; < -1 = low quality) to indicate high and low quality (Swain et 
al., 2013); however, given the low number of studies returned this was not possible 
here. Also, some items of the POMRF are of limited applicability to long-term 
conditions. Here two items regarding the certainty of diagnosis appeared superfluous 
and no assessment of whether outcomes were self-report or directly measured was 
included. Composition of specific quality assessment criteria for psychological 
intervention studies with long-term conditions is recommended.  
Where effect-sizes were not already reported in RCTs we calculated effect size 
based on comparison between post-intervention score. The accuracy of the resultant 
effect size thus relies on the assumption that pre-intervention scores are equivalent 
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between conditions–which seems unlikely. Also, when calculating within-group effect 
sizes we were unable to account for the correlation between the pre- and post- 
intervention variables; therefore, these effect sizes may be slightly inaccurate  
(see(Lakens, 2013)).   
Finally, we did not include studies with chronic pain populations, which might 
be considered an oversight since chronic pain is often experienced in long-term 
conditions (Clifford & Trotter, 1984; Jensen et al., 2008). The exclusion was for two 
reasons: First and foremost, due to the implication that ACT is being used clinically but 
that there has been no systematic review of ACT specifically in long term conditions, 
this reviewed aimed to collate intervention studies accurately describe the field.  In 
contrast to the literature described in the present review, ACT interventions for chronic 
pain are well-reviewed elsewhere (Veehof et al., 2011; McCracken & Vowles, 2014). 
Here, estimation of pooled effect sizes suggests that ACT is effective for chronic pain, 
with a small-to-medium effect size (Veehof et al, 2011). Secondly,  interventions for 
chronic pain, such as those included in the preceeding reviews, often include people 
with pain which is not generated as part of a chronic disease/long-term condition (e.g. 
back pain as a result of aging or sports injury, period pain, or an unknown cause) 
(Veehof et al., 2011; Elliott et al., 1999). Indeed, here in the UK people with chronic 
pain are often treated by specialist pain management services (Barker & McCracken, 
2013) , such services being somewhat distinct from services for chronic health 
conditions – e.g. Psycho-oncology, Neuropsychology etc. 
CONCLUSION  
ACT has been applied in many different ways within a range of long-term conditions. 
However, there have been no trials of ACT for improving medication non-adherence. 
Most of the included studies were low quality and there were very few RCTs. 
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Therefore, ACT interventions are not yet well established for use in long-term 
conditions. Nonetheless, encouraging results suggest that these interventions are worthy 
of further investigation in this context. In particular, there is promising evidence that 
ACT may improve the parenting of children with long-term conditions, seizure-control 
in epilepsy, psychological flexibility and possibly disease self-management/lifestyle.  
A GENERAL CONCLUSION TO THE THESIS 
Chapter 1 demonstrated that psychological flexibility s more strongly predictive 
of change in life satisfaction and anxiety over time than illness perceptions (with neither 
predictive of depression). Ostensibly, these findings suggest that interventions which 
focus on improving psychological flexibility may prove beneficial in muscle disorder 
care. However, the main caveat to this finding was th t causality could not be 
established due mostly to the observational design. Therefore, it cannot be said that if 
one improves psychological flexibility then life satisfaction and anxiety will change as a 
result. Experimental methods which manipulate psychological flexibility are required to 
strengthen a case for causality.  
ACT is a psychological therapy which is specifically designed to improve 
psychological flexibility. Given the findings of Chapter 1, we sought to examine its 
application in long-term conditions (comparable contexts to muscle disorders). This 
demonstrated that ACT has been applied in many ways to improve outcomes across 
conditions. However, despite encouraging results for ome specific applications, the 
general quality of evidence was quite low and there were few RCT evaluations per 
application. Indeed, while improvements following ACT were seen for QoL and 
distress, there was little clear evidence that this wa  not due to regression to the mean or 
non-specific therapy factors. The implication for interventions with muscle disorders is 
that one cannot generalise that: ACT should improve these outcomes in muscle 
 80
disorders because this is clearly established in a s milar context (i.e. with other long-
term conditions). However, encouragingly the interventions did appear feasible and 
generally beneficial. Indeed, importantly the systematic review observed promising 
evidence that psychological flexibility may be changed as a result of ACT.  
Therefore the findings and limitations of the two studies lead to one conclusion. 
In the context of muscle disorders which are associated with significant reductions in 
QoL (Burns et al., 2012; Graham et al., 2011) and for which medical treatment is 
limited, there is a suggestion that psychological flexibility might help explain variation 
in QoL/life satisfaction and mood. An RCT (of ACT) is an experimental design which 
will allow us to establish if psychological flexibility can be manipulated to improve 
outcomes, but more importantly if psychological intervention can improve outcomes in 
muscle disorders. With a lack of available generalisab le findings regarding efficacy 
from other long-term conditions, I would thus suggest that steps are now made towards 
undertaking such a trial with muscle disorders.  
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APPENDIX FOR CHAPTER ONE 
(i) Exploratory Factor Analysis of Brief IPQ  
Exploratory Factor Analysis of the Brief IPQ 
 
Due to poor internal consistency the 8-item scale was subjected to a principal 
component analysis (Varimax rotation). The Kaiser-Meyer-Olkin measure (KMO = .63) 
suggested moderate sampling adequacy (Field, 2009), and KMO values for the 
individual items ranged from .49 - .70. Bartlett’s e t of Sphericity X2 (137) = 167.98, p 
<.001, indicated that inter-correlations between itms were acceptable for principal 
component analysis. Using Kaiser’s criterion, three variables in combination explained 
61.58% of the variance, points of inflection on thescree plot suggested retention of 
between one and three variables. Given that Kaiser’s criterion lay within this range, 
three variables were extracted. These variables had internal consistency of α = .71 
(emotional representation, consequences, concern and ide tity); α = .38 (coherence and 
personal control); and, α =.24 (timeline and treatment control). Factor 1 showed 
acceptable internal consistency, items were conceptually similar, and the concept of this 
item was commensurate with the planned overall scale (i.e. it appeared to measure 
illness threat as would be measured by the whole Brief IPQ scale). Thus factor 1 was 
retained in the analyses. Given that factors 2 and 3 lacked conceptual consistency and 
had poor internal consistency these were omitted.  
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(ii)  Assumptions of normality for regression analyses 
Assumptions for regressions involving the SWLS 
The assumptions for multiple regression as described by Field (2009) were 
considered. A brief description of each assumption, h w it should be evaluated using 
SPSS, the performance of the present data and solutions are listed below.  
 
Normally distributed dependent variables 
Dependent variables must have at least an approximately normal distribution for 
regression analysis to be valid. Normality involves the distribution of responses across 
the possible data points of a given measure. Normal dat  follows a bell-curve 
distribution with greater frequency of response at central points. Skewness and kurtosis 
indicate  non-normal distributions: kurtosis refers to the peakedness of the distribution, 
 92
whilst skewness regards the symmetry of the distribution. As suggested by Field (2009) 
we used histograms and normality plots to assess th normality of data. The 
Kolmogorov-Smirnov statistic was also inspected; however this may be over-sensitive 
to any violations of normality (Field, 2009), and therefore visual inspection of normality 
plots was the predominant measure. As you can see from the below histograms and 
normality plots (Table A1; Figures A2-A5), both the SWLS measured at time one, and 




Tests of Normality 
 Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
SWLS11 .093 137 .005 .970 137 .004 
SWLST22 .077 137 .045 .966 137 .002 












Figure A4                                                              Figure A5 
 
 
Normally distributed independent variables  
Field (2009) suggests that due to central limit theorem, non-normally distributed 
independent variables are unlikely to invalidate th model in larger samples, but may 
influence smaller sample sizes.  The present sample was of adequate sample size for the 
number of predictors; however, it could not be described as a large sample size (N 
=127). Thus non-normal predictor variables were transformed where possible.  See 
below for normality indicators (Kolmogorov-Smirnov Test; histograms and normality 
plots of predictors), (Table A2; Figures A6-A15) and subsequent transformations (Table 
A3; Figures A16- A19).  
 
Table A2 
Tests of Normality 
 Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
HAQ-ALT .105 137 .001 .930 137 .000 
IPQ_CCIE11 .074 137 .064 .979 137 .031 
AAQ9 .057 137 .200* .992 137 .615 
CFQ .106 137 .001 .946 137 .000 
ELSrecT .070 137 .198 .968 137 .003 
*. This is a lower bound of the true significance. 






Figure A6           Figure A7 
  















Figure A14      Figure A15 
 
Given the non-normality displayed by the HAQ (negative skew) and CFQ 
(positive skew), several transformations were tried. A Log10 transformation gave the 
most normal distribution for the HAQ, while a square route transformation gave the 
most normal distribution for the CFQ; however, the distributions remained non-normal 




Tests of Normality 
 Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
HAQrLog10RRR .085 137 .018 .962 137 .001 
CFQ_Sqrt2 .084 137 .019 .967 137 .002 











Figure A18     Figure A19 
 
Linearity & Homoscedasticity 
Multiple regression is based on the linear model. The assumption of linearity 
relates to whether the effects we are modelling can be described using this model (Field, 
2009). It is also important that variance in residual terms should be should be equal at 














The plot for each of the three regressions is present d in Figures A20 – A22. 
Here, scatter plots revealed that assumptions of homoscedasticity (no funnelling of 
points on the graph) and linearity (no obvious curve pattern) were met for regressions 2 
and 3 (Figure A21- A22)(Field, 2009). However there was some suggestion of 
homoscedasticity (slight funnelling of points on the graph) for regression 1. As this was 
not severe, it was expected that this should not bias the regression (Figure A20). 
 
Independent errors 
An association between the residual terms of any two observations also 
invalidates our model. This assumption was tested by using the Durbin-Watson test. 
This test statistic can range from 0-4. Field (2009) suggests that a value between one 
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and three is unlikely to be cause for concern. In regression one (with SWLS at time one 
as the dependent variable) the Durbin-Watson statistic was 1.87. 
In regression two (with SWLS measured at time two as the dependent variable) 
the Durbin-Watson statistic was 2.00. In regression three (with SWLS measured at time 
two as the dependent variable and SWLS measured at time one included in the 
regression) the Durbin-Watson statistic was 2.42. 
 
Normally distributed errors 
Regression assumes that the residual terms are normally distributed, resulting in 
a mean of 0. As recommended by Field (2009), histograms and normality plots were 
inspected to assess whether this assumption was met. As illustrated in Fig A23-A28, the 
residual terms were approximately normally distributed.  
  
Figure A23     Figure A24 
 
 
Fugure A25     Figure A26 
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Figure A27      Figure A28 
 
Multi-collinearity 
Given that multiple regression was used, it is important that no perfect linear 
relationships are observed between the predictor variables. The variance inflation factor 
(VIF), which assesses the strength of the relationship between each individual predictor 
and the other predictors, was used to assess multi-collinearity. The largest VIF should 
be less than 10 and the average VIF should not be su stantially greater than 1 (Field, 
2009). A tolerance statistic, dervived from the VIF, should also remain above 0.2 (Field, 
2009).  
In regression one (with SWLS measured at time one as the dependent variable) 
VIF ranged from 1.08– 2.23, average VIF was 1.33, with tolerance ranging from 0.45 – 
0.93. Regression two (with SWLS measured at time two as the dependent variable) VIF 
ranged from 1.00 – 2.23, average VIF was 1.73, withtolerance ranging from 0.45 – 
0.93. In regression three (with SWLS measured at time wo as the dependent variable 
and SWLS measured at time one included in the regression) VIF ranged from  1.00 – 
3.71, average VIF was 2.11, with tolerance ranging from 0.33 -0.91 
 
Outliers 
Field (2009) suggests that regression analysis is sen itive to outliers. In the 
present analysis we used Mahalanobis distance (the distance of a case from the means of 
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all other cases, with the centriod created using the means of all standardised variables 
[Field, 2009]) to assess for the presence of outliers. Using a a table of critical values 
derived from number of predictors and sample size, (Bartnett & Lewis 78), it was 
established that distances of greater than 22 were lik ly to indicate an influential outlier 
in the present sample. In regression one the greatest Mahalanobis distance was 20.71.  
In regression two the greatest Mahalanobis distance was 20.71.  In regression three, the 
greatest Mahalanobis distance was 20.91.   
 
Assumptions for regressions involving the GAD-7 
This appendix details the results of the preliminary analysis for regressions 
where the GAD-7 was the dependent variable.   
 
Normally distributed dependent variables 
As you can see from the below histograms and normality plots, both the GAD-7 
measured at time one, and the GAD-7 measured at time two had a non- normal 
distribution, with a positive skew (Table A4; Figures A29-32). Several transformations 
were tried, but only an approximate transformation was possible (Square route) for both 
variables (Table A5; Figures A33-36). As recommended by Field (2009), given that a 
non-normal distribution can affect the validity of results, robust regression procedures 




Tests of Normality 
 Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
GAD_TOT11 .165 137 .000 .834 137 .000 
GADTot22 .176 137 .000 .853 137 .000 
 101




Figure A29     Figure A30 
 




Tests of Normality 
 Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
GAD_SQ .104 137 .001 .956 137 .000 
GAD2_SQ .130 137 .000 .946 137 .000 




Figure A33     Figure A34 
 
  
Figure A35              Figure A36 
Normally distributed independent variables  
The previous section (assumptions for SWLS regression ) outlines the normality 
of predictor variables and subsequent transformations. 
 
Linearity & Homoscedasticity 
The scatter plots (Figures A37-A39) revealed that assumptions of 
homoscedasticity (no funnelling of points on the graph) and linearity ( no obvious curve 











In regression one the Durbin-Watson statistic was 1.85. In regression two the 
Durbin-Watson statistic was 2.24. In regression three the Durbin-Watson statistic was 
2.09. 
 
Normally distributed errors 
Regression assumes that the residual terms are normally distributed, resulting in 
a mean of 0. As recommended by Field (2009), histograms and normality plots were 
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inspected to assess whether this assumption was met. As illustrated in Figures A40-A45 
these were approximately normally distributed.  
 
  
Figure A40     Figure A41 
  
Figure A42     Figure A43 
  




In regression one VIF ranged from  1.27– 1.41, averg  VIF was 1.33, with 
tolerance ranging from 0.71 – 0.79. In regression twoVIF ranged from  1.08 – 2.23, 
average VIF was 1.73, with tolerance ranging from 0.45 – 0.93. In regression three VIF 




In regression one the greatest Mahalanobis distance was 20.71.  In regression 
two the greatest Mahalanobis distance was 20.71.  In regression three the greatest 
Mahalanobis distance was 21.34.   
 
Assumptions for regressions involving the PHQ-9 
This appendix details the results of the preliminary analysis for regressions 
where the PHQ-9 was used as the dependent variable.  The assumptions for multiple 
regression as described by Field (2009) are listed below.  
 
 
Normally distributed dependent variables 
As illustrated in the below histograms and normality plots, both the PHQ-9 
measured at time one, and the PHQ-9 measured at time wo had non- normal 
distributions, with a positive skew (Table A6; Figures A46-49). Several transformations 
were tried, but only an approximate transformation was possible (Square route) for both 
variables (Table A7 Figures A50-53). As recommended by Field (2009), given that a 
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non-normal distribution can affect the validity of results, robust regression procedures 
were used in all regressions where PHQ-9 was the dep ndent variable. 
 
Table A6 
Tests of Normality 
 Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
PHQTOT11 .137 137 .000 .920 137 .000 
PHQTot .131 137 .000 .925 137 .000 









Figure A48      Figure A49 
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Table A7 
Tests of Normality 
 Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
PHQ_SQ .073 137 .069 .975 137 .014 
PHQ2_SQ .090 137 .009 .961 137 .001 










Figure A52     Figure A53 
 
 
Normally distributed independent variables  
 See the previous section (assumptions for regression  involving the SWLS) which 
outlines the normality of independent variables andsubsequent transformations. 
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Linearity & Homoscedasticity 
The scatter plots revealed that assumptions of homoscedasticity (no funnelling of points 





Figure A54      Figure A55 
 




 In regression one the Durbin-Watson statistic was 2.11. In regression two the 




Normally distributed errors 
Histograms and normality plots were inspected to asses  whether this 




Figure A57      Figure A58 
 
  
Figure A59      Figure A60 
 
  





In regression one VIF ranged from 1.08– 2.07, average VIF was 1.63, with 
tolerance ranging from 0.48 – 0.92. In regression two VIF ranged from 1.08 – 2.07, 
average VIF was 1.63, with tolerance ranging from 0.48 – 0.92. In regression three VIF 
ranged from 1.08 – 2.08, average VIF was 1.70, withtolerance ranging from 0.52 -0.92. 
 
Outliers 
In regression one the greatest Mahalanobis distance was 21.02.  In regression 
two the greatest Mahalanobis distance was 21.02.  In regression three the greatest 
Mahalanobis distance was 22.07.   
 
Additional References  
Barnett, V., & Lewis, T. (1978). Outliers in statistical data. New York: Wiley 













(iii)  Extended versions of the regression tables  
Table a. Three regressions showing the cross-sectional and prospective influence of 
independent variables on life satisfaction (SWLS). 
 
 
A. Crossectional: all variables at T1 
Step Variable β t p R2 ∆R2  
∆F 
p 
1 Disability Level (HAQ-DI) -.11 -1.29 .20 .01 .01 1.68 .20 
2 Disability Level (HAQ-DI) .01 0.11 .92 .27 .26 47.92 <.001 
 Illness Threat 
(IPQ-Threat) 
-.52 -6.92 <.001     
3 Disability Level (HAQ-DI) -.08 -1.47 .14 .62 .34 39.22 <.001 
 Illness Threat 
(IPQ-Threat) 
-.22 -3.27 .001     
 Experiential Avoidance (AAQ) -.10 -1.22 .23     
 Cognitive Fusion (CFQ) .13 1.81 .07     
 Valued-living (ELS) .66 8.75 <.001     
  
B. Prospective: Independent variables at T1; Dependent variables at T2 
  
Step Variable β t p R2 ∆R2  
∆F p 
1 Disability Level (HAQ-DI) -.10 -1.19 .27 .01 .01 1.25 .27 
2 Disability Level (HAQ-DI) .01 0.09 .94 .20 .19 32.34 <.001 
 Illness Threat 
(IPQ-Threat) 
-.45 -5.69 <.001     
3 Disability Level (HAQ-DI) -.07 -0.98 .33 .43 .23 17.65 <.001 
 Illness Threat 
(IPQ-Threat) 
-.23 -2.79 .01     
 Experiential Avoidance (AAQ) -.28 -2.84 .01     
 Cognitive Fusion (CFQ) .30 3.34 .01     
 Valued-living (ELS) .45 4.89 <.001     
 C. Prospective: Independent variables at T1; Dependent variables at T2 controlling for T1. 
 
Step Variable β t p R2 ∆R2  
∆F p 
1 T1 Life Satisfaction (SWLS) .72 12.14 <.001 .52 .52 147.31 <.001 
2 T1 Life Satisfaction (SWLS) .72 11.99 <.001 .52 .00 0.72 .789 
 Disability Level (HAQ-DI) -.02 -.27 .79     
3 T1 Life Satisfaction (SWLS .67 9.61 <.001 .52 .01 1.95 .165 
 Disability Level (HAQ-DI) .00 0.02 .99     
 Illness Threat 
(IPQ-Threat) 
-.10 -1.40 .17     
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4 T1 Life Satisfaction (SWLS) .59 6.33 <.001 .55 .04 3.65 .014 
 Disability Level (HAQ-DI) -.02 -0.30 .77     
 Illness Threat 
(IPQ-Threat) 
-.10 -1.32 .19     
 Experiential Avoidance (AAQ) -.22 -2.55 .01     
 Cognitive Fusion (CFQ) .22 2.78 .01     
 Valued-living (ELS) .06 0.58 .57     
         
Method: Enter 
 
SWLS= Satisfaction with Life Scale; HAQ-DI = Health Assessment Questionnaire – 
Disability Index; IPQ Threat = Brief Illness Perception Questionnaire Threat Scale; 
AAQ = Acceptance and Action Questionnaire; CFQ = Cognitive Fusion Questionnaire; 





































Table b. Three regressions showing the cross-sectional and prospective influence of 
independent variables on anxiety (GAD 7)†  
 
 
A. Crossectional: all variables at T1 
Step Variable β t p R2 ∆R2  
∆F p 
1 Disability Level (HAQ-DI) .02 0.25 .80 -.01 .00 0.06 .801 
2 Disability Level (HAQ-DI) -.10 -1.26 .25 .25 .26 46.18 <.001 
 Illness Threat 
(IPQ-Threat) 
.52 6.80 <.001     
3 Disability Level (HAQ-DI) -.04 -0.59 .60 .47 .23 19.75 <.001 
 Illness Threat 
(IPQ-Threat) 
.20 -2.58 .02     
 Experiential Avoidance (AAQ) .03 -0.35 .69     
 Cognitive Fusion (CFQ) .38 4.50 <.001     
 Valued-living (ELS) -.23 -2.67 .016     
 B. Prospective: Independent variables at T1; Dependent variables at T2 
 
Step Variable β t p R2 ∆R2  
∆F p 
1 Disability Level (HAQ-DI) -.07 -0.80 .42 .01 .01 0.64 .43 
2 Disability Level (HAQ-DI) -.17 -2.10 .03 .19 .18 30.09 <.001 
 Illness Threat 
(IPQ-Threat) 
.44 5.49 .00     
3 Disability Level (HAQ-DI) -.11 -1.52 .15 .41 .22 16.53 <.001 
 Illness Threat 
(IPQ-Threat) 
.12 1.42 .27     
 Experiential Avoidance 
(AAQ) 
-.06 0.64 .56     
 Cognitive Fusion (CFQ) .31 3.42 .01     
 Valued-living (ELS) -.27 -2.92 <.01     
 C. Prospective: Independent variables at T1; Dependent variables at T2 controlling for T1. 
 
Step Variable β t p R2 ∆R2  
∆F p 
1 T1 Anxiety (GAD-7) .75 12.96 <.001 .56 .56 168.07 <.001 
2 T1 Anxiety (GAD-7) .75 13.05 <.001 .56 .01 2.20 .14 
 Disability Level (HAQ-DI) -.09 -1.48 .17     
3 T1 Anxiety (GAD-7) .71 10.75 <.001 .57 .00 1.00 .32 
 Disability Level (HAQ-DI) -.10 -1.69 .11     
 Illness Threat 
(IPQ-Threat) 
.07 1.00 .31     
4 T1 Anxiety (GAD-7) .59 7.58 <.001 .59 .03 2.78 .04 
 Disability Level (HAQ-DI) -.08 -1.42 .17     
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 Illness Threat 
(IPQ-Threat) 
.00 -0.01 .99     
 Experiential Avoidance (AAQ) .05 -0.53 .67     
 Cognitive Fusion (CFQ) .08 1.03 .35     
 Valued-living (ELS) -.14 -1.68 .11     
         
Method: Enter 
 
GAD-7= General Health Questionnaire 7 item version; HAQ-DI = Health Assessment 
Questionnaire – Disability Index; IPQ Threat = Brief Illness Perception Questionnaire 
Threat Scale; AAQ = Acceptance and Action Questionnaire; CFQ = Cognitive Fusion 
Questionnaire; ELS = Engaged Living Scale. 
 





































Table c. Three regressions showing the cross-sectional and prospective influence of 
independent variables on depression (PHQ 9) †. 
 
 
A. Crossectional: all variables at T1 
Step Variable β t p R2 ∆R2  
∆F p 
1 Disability Level (HAQ-DI) .08 0.97 .33 .01 .01 0.95 .332 
2 Disability Level (HAQ-DI) -.04 -0.50 .61 .28 .27 50.53 <.001 
 Illness Threat 
(IPQ-Threat) 
.54 7.11 <.001     
3 Disability Level (HAQ-DI) .02 0.31 .77 .45 .17 13.06 <.001 
 Illness Threat 
(IPQ-Threat) 
.26 3.16 .02     
 Experiential Avoidance (AAQ) .08 0.87 .34     
 Cognitive Fusion (CFQ) .20 2.22 .09     
 Valued-living (ELS) -.28 -3.10 <.01     
  
B. Prospective: Independent variables at T1; Dependent variables at T2 
  
Step Variable β t p R2 ∆R2  
∆F p 
1 Disability Level (HAQ-DI) .06 0.71 .49 .00 .00 0.50 .48 
2 Disability Level (HAQ-DI) -.04 -0.50 .62 .19 .19 30.79 <.001 
 Illness Threat 
(IPQ-Threat) 
.44 5.55 .00     
3 Disability Level (HAQ-DI) .01 0.15 .87 .31 .12 7.79 <.001 
 Illness Threat 
(IPQ-Threat) 
.19 2.08 .06     
 Experiential Avoidance 
(AAQ) 
.18 1.66 .06     
 Cognitive Fusion (CFQ) .16 1.60 .18     
 Valued-living (ELS) -.16 -1.59 .11     
 C. Prospective: Independent variables at T1; Dependent variables at T2 controlling for T1. 
 
Step Variable β t p R2 ∆R2  
∆F p 
1 T1 Depression (PHQ-9) .83 17.06 <.001 .68 .68 291.06 <.001 
2 T1 Depression (PHQ-9) .83 16.95 <.001 .68 .00 0.03 .86 
 Disability Level (HAQ-DI) -.01 -0.17 .88     
3 T1 Depression (PHQ-9) .83 14.39 <.001 .68 .00 0.00 .99 
 Disability Level (HAQ-DI) -.01 -0.17 .87     
 Illness Threat 
(IPQ-Threat) 
.00 0.00 .99     
4 T1 Depression (PHQ-9) .82 12.56 <.001 .69 .01 0.84 .47 
 Disability Level (HAQ-DI) -.01 -0.11 .91     
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 Illness Threat 
(IPQ-Threat) 
-.02 -0.36 .70     
 Experiential Avoidance (AAQ) .11 -1.50 .12     
 Cognitive Fusion (CFQ) -.01 -0.07 .96     
 Valued-living (ELS) .07 1.01 .37     
         
Method: Enter 
 
PHQ-9= Patient Health Questionnaire 9-item version; HAQ-DI = Health Assessment 
Questionnaire – Disability Index; IPQ Threat = Brief Illness Perception Questionnaire 
Threat Scale; AAQ = Acceptance and Action Questionnaire; CFQ = Cognitive Fusion 
Questionnaire; ELS = Engaged Living Scale. 
 



























(iv) Online materials  
 
 
Figure B1. Online advertisement 
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Figure B2.Part of the Information sheet  
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Figure B3. The consent form 
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(v) Redacted Ethics Approval Form 
University of Edinburgh, School of Health in Social Science  
RESEARCH ETHICS APPLICATION (REA) 
The forms required when seeking ethical approval in the School of 
Health and Social Sciences have now been merged into this single electronic document.  The 
sections you are required to complete will depend on the nature of your application.  Please 
start to complete the form from the beginning and proceed as guided.  On completion the 
entire document should be submitted electronically to your section’s ethics tutor using the 
email addresses detailed on the final page. 
 
 




I can confirm that the above application has been reviewed by two independent reviewers.  It is their 
opinion that: 
 
a) The ethical issues listed below arise or require clarification: 
 
• In the advert , the website for the questionnaire should only appear at the end. Currently there is 
a link provided half-way through the document, this should be removed. 
• An independent advisor to the study contact could be provided both in the advert and on the 
participant information sheet. 
• The consent form should make evident that data collected will be stored in a secured place, that it 
will be non-identifiable, and that all identifiable data will be destroyed. 
• We ask if there is a more suitable source of help to direct participants in distress too that NHS 24 / 
Direct?  These helplines have limited capacity to deal with psychological distress. 
 
 
The applicant should respond to these comments in section 8 below. 
Signature:   
Position: Ethics Tutor 
Date:                 14.11.2013 
 
ER36 APPLICANT’S RESPONSE (If required) 
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Dear Reviewers, 
Thank you for your detailed feedback on this ethics application, and apologies 
that it was an overly-long application. Below I list how I have addressed each of the issues that you specify 
above: 
 
1. The link has been removed from the middle of the advert and placed at 
the end. 
2. An independent point of contact has been placed on the information 
sheet and advert. 
3. The consent form has been modified to include your suggestion. 
4. We understand your concern regarding the use of the NHS 24 telephone 
number, however having considered this point, we think it is important that this contact number remains 
in the information sheets/thank you message. This is because, whilst we are aware that NHS 24 cannot 
directly treat any immediate distress, they will be able to suggest appropriate courses of action given the 
need of the caller - thus in a sense triage the level of need. Indeed this has been found acceptable by NHS 
ethics committees in my own previous NHS ethics applications. We will however provide a link to the 
mental health helpline which are suggested by the NHS (http://www.nhs.uk/Conditions/stress-anxiety-
depression/Pages/mental-health-helplines.aspx) to allow participants to access other services under their 
own volition, if they so wish. I hope that this course of actions helps attenuate your concerns. 
 







ER37 CONCLUSION TO ETHICAL REVIEW (if required) 
 
The applicant’s response to our request for further clarification or amendments has now satisfied the 
requirements for ethical practice and the application has therefore been approved. 
 
signature:  
Position: Ethics Tutor 









APPENDIX FOR CHAPTER TWO 

































































































































1. Clarity of sample 
description 
2 0 0 2 2 2 2 2 2 0 0 
2. Severity/chronicity of 
the disorder 
 - -  -  - -  -  -   - -  -  -  
3. Representativeness  1 2 1 2 2 2 2 2 2 1 2 
4.Reliability of the 
diagnosis 
 -  -  -  -  -  -  -  -  -  -  - 
5. Specificity of outcome 
measures 
2 2 2 2 2 2 1 1 1 1 2 
6. Reliability and validity 
of outcomes 
1 2 2 2 1 2 2 2 2 2 2 
7.  Use of blind evaluators 0 0 0 0 0 2 0 0 0 0 0 
8. Assessor training 0 0 0 0 0 1 0 0 0 0 0 
9. Assignment to 
treatment 
2 0 0 0 2 2 1 1 1 2 2 
10. Design 1 0 0 0 1 1 1 2 2 2 2 
11. Power analysis 0 0 0 0 2 2 0 0 0 0 2 




2 1 1 1 2 1 2 2 2 1 2 
14. Number of therapists 1 0 0 2 1 2 1 0 1 0 1 
15. Therapist training/ 
experience 
2 0 2 0 1 1 2 2 2 1 2 
16. Checks for treatment 
adherence 
2 0 1 1 0 2 0 0 0 0 1 
17. Checks for therapist 
competence 
1 0 1 1 0 2 0 0 0 1 0 
18. Control of 
concomitant treatments 
0 0 0 0 0 0 1 0 0 0 0 
19. Handling of attrition 2 0 1 0 2 1 1 1 1 2 2 
20. Stats analysis and 
presentation of results 
2 2 2 2 2 2 2 2 1 2 2 
21. Clinical significance 2 0 1 0 1 1 0 0 0 0 0 
22. Equality of therapy 
hours 
0 0 0 0 0 0 2 2 2 2 0 
Total quality  24 10 15 15 21 30 22 21 20 17 23 
Total quality  AVE 1.2 0.5 0.75 0.75 1.05 1.5 1.1 1.05 1 0.85 1.15 
 
 
